<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Vaccines</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Vaccines</journal-id><journal-id journal-id-type="pmc-domain-id">3297</journal-id><journal-id journal-id-type="pmc-domain">npjvac</journal-id><journal-title-group><journal-title>NPJ Vaccines</journal-title></journal-title-group><issn pub-type="epub">2059-0105</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9734748</article-id><article-id pub-id-type="pmcid-ver">PMC9734748.1</article-id><article-id pub-id-type="pmcaid">9734748</article-id><article-id pub-id-type="pmcaiid">9734748</article-id><article-id pub-id-type="pmid">36494369</article-id><article-id pub-id-type="doi">10.1038/s41541-022-00587-6</article-id><article-id pub-id-type="publisher-id">587</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Urgency and necessity of Epstein-Barr virus prophylactic vaccines</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2397-2115</contrib-id><name name-style="western"><surname>Zhong</surname><given-names initials="L">Ling</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Krummenacher</surname><given-names initials="C">Claude</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="W">Wanlin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hong</surname><given-names initials="J">Junping</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Feng</surname><given-names initials="Q">Qisheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9591-634X</contrib-id><name name-style="western"><surname>Chen</surname><given-names initials="Y">Yixin</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="Q">Qinjian</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3509-5591</contrib-id><name name-style="western"><surname>Zeng</surname><given-names initials="MS">Mu-Sheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zeng</surname><given-names initials="YX">Yi-Xin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7091-4199</contrib-id><name name-style="western"><surname>Xu</surname><given-names initials="M">Miao</given-names></name><address><email>xumiao@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6655-2463</contrib-id><name name-style="western"><surname>Zhang</surname><given-names initials="X">Xiao</given-names></name><address><email>103193@cqmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.12981.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2360 039X</institution-id><institution>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, </institution><institution>Sun Yat-sen University, </institution></institution-wrap>Guangzhou, Guangdong PR China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.262671.6</institution-id><institution-id institution-id-type="ISNI">0000 0000 8828 4546</institution-id><institution>Department of Biological and Biomedical Sciences, </institution><institution>Rowan University, </institution></institution-wrap>Glassboro, NJ USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.12955.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2264 7233</institution-id><institution>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, </institution><institution>Xiamen University, </institution></institution-wrap>Xiamen, Fujian PR China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.203458.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 8653 0555</institution-id><institution>College of Pharmacy, </institution><institution>Chongqing Medical University, </institution></institution-wrap>Chongqing, PR China </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>7</volume><issue-id pub-id-type="pmc-issue-id">397527</issue-id><elocation-id>159</elocation-id><history><date date-type="received"><day>26</day><month>7</month><year>2022</year></date><date date-type="accepted"><day>24</day><month>11</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>12</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>11</day><month>12</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-07-03 16:25:30.850"><day>03</day><month>07</month><year>2024</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">9734748</article-id><article-id pub-id-type="doi">10.1038/s41541-022-00587-6</article-id><article-version>1</article-version><pub-date><day>09</day><month>12</month><year>2022</year></pub-date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">9735124</article-id><article-id pub-id-type="doi">10.1038/s41541-022-00587-6</article-id><article-version>2</article-version><pub-date><day>09</day><month>12</month><year>2022</year></pub-date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2022</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41541_2022_Article_587.pdf"/><abstract id="Abs1"><p id="Par1">Epstein-Barr virus (EBV), a &#947;-herpesvirus, is the first identified oncogenic virus, which establishes permanent infection in humans. EBV causes infectious mononucleosis and is also tightly linked to many malignant diseases. Various vaccine formulations underwent testing in different animals or in humans. However, none of them was able to prevent EBV infection and no vaccine has been approved to date. Current efforts focus on antigen selection, combination, and design to improve the efficacy of vaccines. EBV glycoproteins such as gH/gL, gp42, and gB show excellent immunogenicity in preclinical studies compared to the previously favored gp350 antigen. Combinations of multiple EBV proteins in various vaccine designs become more attractive approaches considering the complex life cycle and complicated infection mechanisms of EBV. Besides, rationally designed vaccines such as virus-like particles (VLPs) and protein scaffold-based vaccines elicited more potent immune responses than soluble antigens. In addition, humanized mice, rabbits, as well as nonhuman primates that can be infected by EBV significantly aid vaccine development. Innovative vaccine design approaches, including polymer-based nanoparticles, the development of effective adjuvants, and antibody-guided vaccine design, will further enhance the immunogenicity of vaccine candidates. In this review, we will summarize (i) the disease burden caused by EBV and the necessity of developing an EBV vaccine; (ii) previous EBV vaccine studies and available animal models; (iii) future trends of EBV vaccines, including activation of cellular immune responses, novel immunogen design, heterologous prime-boost approach, induction of mucosal immunity, application of nanoparticle delivery system, and modern adjuvant development.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Vaccines</kwd><kwd>Virology</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China (National Science Foundation of China)</institution></institution-wrap></funding-source><award-id>81702001</award-id><award-id>81872228</award-id><principal-award-recipient><name name-style="western"><surname>Zhang</surname><given-names>Xiao</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2022</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Epstein-Barr virus (EBV) is a &#947;-herpesvirus that contains a double-stranded DNA genome of approximately 172&#8201;kb and is the first identified human oncogenic virus<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. The EBV particle has a typical three-layer structure: the outermost lipid envelope displaying multiple glycoproteins responsible for cell entry, the middle tegument containing 20&#8211;40 proteins, and the inner pseudo-icosahedral nucleocapsid surrounding the DNA genome. The complete atomic models of the EBV icosahedral capsid, dodecameric portal, and capsid-associated tegument complex were resolved recently<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>.</p><p id="Par3">EBV infects more than 95% of humans and establishes a lifelong infection<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. The target cells of EBV infection are B cells, epithelial cells, natural killer (NK)/T cells, and macrophages. In vitro, EBV infection leads to latent infection in B cells and a lytic infection in epithelial cells<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Although the mechanisms of EBV entry into B cells and epithelial cells are very distinct, the fusion triggering protein gH/gL and the fusion protein gB are involved in both processes<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. EBV enters epithelial cells and B lymphoblastoid cells through fusion at the plasma membrane, while endocytosis is required for B lymphocyte infection<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>. To be specific, B cell entry is initiated by the most abundant membrane glycoprotein gp350/gp220 binding to the complement receptor-2 (CD21/CR2) or to CD35 (CR1)<sup><xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref></sup>. Following endocytosis into B lymphocytes<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>, binding of the gp42 C-terminal region of the heterotrimer gH/gL/gp42 to human leukocyte antigens class II (HLA-II), thereby causes the structure to become a &#8220;closed&#8221; state<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. This conformational change is thought to allow gH/gL/gp42 complex to interact with gB to initialize fusion with the endosomal membrane<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. The mechanism of entry into epithelial cells is less well-defined. The first step involves binding BMRF2 to integrins to lessen the distance between the virus and cell<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Then gH/gL binds to ephrin receptor A2 (EphA2) and this interaction is thought to allow gH/gL to induce gB initializing membrane fusion<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. Besides EphA2, &#945;v&#946;5/&#946;6/&#946;8-integrins may also contribute to this process, but their roles have not been clearly defined<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. In addition, the interactions of gH/gL with nonmuscle myosin heavy chain IIA and gB with neuropilin-1 contribute to this process<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>.</p><p id="Par4">The EBV life cycle is complex and involves the expression of approximately 80 viral proteins. The latent-lytic switch is a particularly significant event in the EBV life cycle, but its mechanism remains unknown. Only nine proteins that contribute to B cell transformation and tumorigenesis are expressed during latent infection. They include six EBV nuclear antigens (EBNA-1, -2, -3A, -3B, -3C, and -LP) and three latent membrane proteins (LMP-1, -2A, and -2B)<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>. Lytic infection involves numerous proteins, which can be divided into immediate early, early, and late proteins according to their expression during the different phases of viral replication<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Among these proteins, the immediate early proteins Zta (BZLF-1) and Rta (BRLF-1) act as triggers of the EBV lytic cycle<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Immediate early and early proteins control genome replication and expression of late proteins<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Many lytic gene products remain to be characterized as their functions are still unclear<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>.</p><p id="Par5">Even though EBV infection is associated with different pathologies, prophylactic or therapeutic vaccines are not yet available. In this review, we will summarize (i) the disease burden caused by EBV and the necessity of developing an EBV vaccine; (ii) previous EBV vaccine studies, available animal models, and human clinical trials; (iii) future trends of EBV vaccine studies, including activation of cellular immune responses, novel immunogen design, heterologous prime-boost approach, induction of mucosal immunity, application of nanoparticle delivery system, and modern adjuvant development.</p></sec><sec id="Sec2"><title>Why do we need an EBV vaccine?</title><p id="Par6">EBV is the pathogenic agent of diseases like infectious mononucleosis (IM), oral hairy leukoplakia (OHL), chronic active EBV disease (CAEBV), autoimmune diseases, and several malignancies (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>EBV-associated diseases and latency states.</title><p>Primary EBV infection can cause infectious mononucleosis (IM), which also increases the risk of Hodgkin&#8217;s lymphoma (HL) and multiple sclerosis (MS). EBV aberrant lytic activity is associated with oral hairy leukoplakia (OHL), chronic active EBV disease (CAEBV). EBV infection and reactivation cause several autoimmune diseases, including rheumatoid arthritis (RA), Sj&#246;gren&#8217;s syndrome (SS), systemic lupus erythematosus (SLE), and MS through molecular mimicry. Besides, EBV is tightly associated with various lymphomas, including Burkitt&#8217;s lymphoma (BL), HL, natural killer/T-cell lymphoma (NKTL), as well as epithelial malignancies such as gastric carcinoma (GC) and nasopharyngeal carcinoma (NPC). The EBV latency state in HL, NKTL, and NPC is type II, while BL and GC display EBV latency type I. Besides these cancers, EBV latency is also associated to lymphoproliferative diseases in patients after stem cell transplantation or solid organ transplantation (PTLD). The figure was made from Biorender.com.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e469" position="float" orientation="portrait" xlink:href="41541_2022_587_Fig1_HTML.jpg"/></fig></p><p id="Par7">EBV primary lytic infection is associated with IM<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. EBV primary infection in young children and adolescents remains asymptomatic, but young adults infected by EBV often develop IM, which also increases the risk of Hodgkin&#8217;s lymphoma (HL) and multiple sclerosis (MS)<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>. Boys with X-linked lymphoproliferative disease type I often develop severe IM after primary EBV infection, which may even become fatal<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. Besides, EBV aberrant lytic activity is associated with OHL and CAEBV<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>.</p><p id="Par8">Recently, as reported, EBV reactivation has been reported to enhance COVID-19 severity<sup><xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR36">36</xref></sup>. EBV infection and reactivation also contribute to the pathogenesis of several autoimmune diseases, including rheumatoid arthritis (RA), Sj&#246;gren&#8217;s syndrome (SS), systemic lupus erythematosus (SLE), and MS<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>. The EBV-specific antibodies and T cells generated during EBV infection and reactivation may react with autologous antigens and then causes autoimmune diseases<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>. Recently, a longitudinal study of a large cohort of subjects strongly supports the link between EBV infection and multiple sclerosis (MS)<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. The risk of MS increased 32-fold after EBV infection<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Besides, antibodies against EBV nuclear antigen-1 (EBNA-1) induced during EBV infection cross-reacts with the central nervous system protein glial cell adhesion molecule and this molecular mimicry contributes to MS development<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. However, molecular mimicry may be only one of the factors contributing to autoimmune disease pathogenesis.</p><p id="Par9">EBV is tightly associated with various lymphomas, including Burkitt&#8217;s lymphoma (BL), HL, natural killer/T-cell lymphoma (NKTL), as well as epithelial malignancies such as gastric carcinoma (GC) and nasopharyngeal carcinoma (NPC)<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. The oncogenic abilities of EBV latent proteins have been widely reported and EBV reactivation contributes to these malignancies<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>. EBV can adopt four latency states that are characterized by different protein expression patterns. Different malignancies are associated with different types of latent infections in the transformed cells (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). The EBV latency state in HL, NKTL, and NPC is type II, while BL and GC display EBV latency type I. Beside these cancers, EBV latency is also associated with lymphoproliferative diseases in patients after stem cell transplantation or solid organ transplantation<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>.</p><p id="Par10">Undoubtedly, EBV causes heavy global public health burdens. As reported, EBV caused 75,000 new cases/year of IM in the USA and 113,205, 105,554, 40,109, and 6318 new cases/year of GC, NPC, HL, and BL worldwide, respectively<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR47">47</xref></sup>. Remarkably, the geographical distribution of nasopharyngeal carcinoma is highly unbalanced and almost half of the new cases are in China, especially in South China<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. In addition, the mortality of EBV-associated malignancies accounts for 1.8% of all cancer deaths<sup><xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR49">49</xref>&#8211;<xref ref-type="bibr" rid="CR51">51</xref></sup>. Although NPC is highly sensitive to radiotherapy and chemotherapy, recurrence and metastasis are very common and linked to poor prognosis<sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup>. BL is a comparatively curable lymphoma, but the long-term survival rate is only 30&#8211;35% for relapsed or refractory BL in pediatric cases<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. Hence, it is very necessary and urgent to develop an EBV prophylactic vaccine to prevent EBV infection and reduce the burden of all its associated diseases.</p></sec><sec id="Sec3"><title>Where are we now?</title><p id="Par11">Due to the inherent tumorigenicity of EBV and the difficulty to achieve high virus production in cell culture, inactivated or attenuated vaccines are not available. From the 1970s onwards, multiple EBV vaccine studies encompassed subunit vaccines, epitope vaccines, DNA vaccines, nanoparticle-based vaccines, viral vector vaccines, virus-like-particles (VLPs), or dendritic cells (DC) vaccines (Table <xref rid="Tab1" ref-type="table">1</xref>). The animal models that can be infected by EBV include humanized mice, rabbits, rhesus macaques (<italic toggle="yes">Macaca mulatta</italic>), common marmosets (<italic toggle="yes">Callithrix jacchus</italic>), cottontop tamarins (<italic toggle="yes">Saguinus oedipus</italic>), and owl monkeys (<italic toggle="yes">Aotus trivirgatus</italic>). In addition, five human clinical trials were completed, but none of these vaccines successfully prevented EBV infection in humans.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Different types of EBV vaccine studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Types</th><th colspan="1" rowspan="1">Antigen</th><th colspan="1" rowspan="1">Formulation</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="13" colspan="1">Subunit vaccine</td><td rowspan="9" colspan="1">gp350</td><td colspan="1" rowspan="1">Subunit gp350 adjuvanted with Freund&#8217;s adjuvant or alum</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Subunit gp350 adjuvanted with Alum</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR55">55</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Subunit gp350 adjuvanted with GLA/SE</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR62">62</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Subunit gp350 adjuvanted with ISCOMs</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR72">72</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Subunit gp350 adjuvanted with SAF-1 or alum</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR60">60</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Subunit gp350 adjuvanted with SAF-1</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup></td></tr><tr><td colspan="1" rowspan="1">gp350 incorporated into liposomes</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR74">74</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Tetrameric and monomeric gp350<sup>1&#8211;470</sup>&#8201;+&#8201;CpG and alum</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR56">56</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Fc-gp350 adjuvanted with CpG OND/Alum</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR79">79</xref></sup></td></tr><tr><td colspan="1" rowspan="1">gB</td><td colspan="1" rowspan="1">Trimeric gB adjuvanted with CpG and alum</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR84">84</xref></sup></td></tr><tr><td colspan="1" rowspan="1">gH/gL</td><td colspan="1" rowspan="1">Trimeric and monomeric gH/gL adjuvanted with CpG and alum</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR84">84</xref></sup></td></tr><tr><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">Glycoprotein complex</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR83">83</xref></sup></td></tr><tr><td colspan="1" rowspan="1">EBNA-1</td><td colspan="1" rowspan="1">&#945;DEC-205-EBNA-1 adjuvanted with poly(I:C)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR95">95</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Epitope vaccine</td><td colspan="1" rowspan="1">gp350</td><td colspan="1" rowspan="1">CTL epitopes of gp350 and gH adjuvanted with TT and IFA</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR67">67</xref></sup></td></tr><tr><td colspan="1" rowspan="1">DC vaccine</td><td colspan="1" rowspan="1">BZLF-1</td><td colspan="1" rowspan="1">DCs transfected to express BZLF-1</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR98">98</xref></sup></td></tr><tr><td rowspan="2" colspan="1">DNA vaccine</td><td colspan="1" rowspan="1">gp350</td><td colspan="1" rowspan="1">pCDNA3.1 plasmid encoding gp350</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR64">64</xref></sup></td></tr><tr><td colspan="1" rowspan="1">gp350</td><td colspan="1" rowspan="1">plasmid of tetrameric gp350<sup>1&#8211;470</sup></td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR56">56</xref></sup></td></tr><tr><td colspan="1" rowspan="1">mRNA vaccine</td><td colspan="1" rowspan="1">gH/gL/gp220/gp42</td><td colspan="1" rowspan="1">mRNA-1189 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05164094">NCT05164094</ext-link>)</td><td colspan="1" rowspan="1">/</td></tr><tr><td rowspan="5" colspan="1">Nanoparticle vaccine</td><td colspan="1" rowspan="1">gH/gL/gp42</td><td colspan="1" rowspan="1">ferritin-gH/gL/gp42&#8201;+&#8201;SAS</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR85">85</xref></sup></td></tr><tr><td rowspan="2" colspan="1">gH/gL</td><td colspan="1" rowspan="1">ferritin-gH/gL&#8201;+&#8201;SAS</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR85">85</xref></sup></td></tr><tr><td colspan="1" rowspan="1">nanoparticle displaying 60 copies of gH/gL</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR86">86</xref></sup></td></tr><tr><td colspan="1" rowspan="1">gp350</td><td colspan="1" rowspan="1">ferritin-gp350&#8201;+&#8201;SAS</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR65">65</xref></sup></td></tr><tr><td colspan="1" rowspan="1">gp350</td><td colspan="1" rowspan="1">LS- or I3-01- gp350 domain I/II/III adjuvanted with MF59</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR66">66</xref></sup></td></tr><tr><td rowspan="8" colspan="1">Virus-like particles (VLPs)</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">EBV-VLPs deleted EBNA-2, LMP-1, EBNA-3A, -B, -C and BZLF-1</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR102">102</xref></sup></td></tr><tr><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">EBV-VLPs deleted BFLF-1/BFRF-1A or BBRF-1</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR103">103</xref></sup></td></tr><tr><td colspan="1" rowspan="1">gp350/gB/gp42/gH/gL</td><td colspan="1" rowspan="1">NDV-VLPs-gp350, gB, gp42, gH and gL</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR87">87</xref></sup></td></tr><tr><td colspan="1" rowspan="1">gH/gL/EBNA-1</td><td colspan="1" rowspan="1">NDV-VLPs-gH/gL-EBNA-1</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR100">100</xref></sup></td></tr><tr><td colspan="1" rowspan="1">gB/LMP-2</td><td colspan="1" rowspan="1">NDV-VLPs- gB-LMP-2</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR100">100</xref></sup></td></tr><tr><td rowspan="2" colspan="1">gp350</td><td colspan="1" rowspan="1">NDV-VLPs-gp350</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR75">75</xref></sup></td></tr><tr><td colspan="1" rowspan="1">HBc149 displaying immunodominant epitopes of gp350</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR78">78</xref></sup></td></tr><tr><td colspan="1" rowspan="1">EBNA-1</td><td colspan="1" rowspan="1">Immunogenic particles containing EBNA-1 + poly (I: C)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR104">104</xref></sup></td></tr><tr><td rowspan="4" colspan="1">Viral vector vaccines</td><td rowspan="2" colspan="1">gp350</td><td colspan="1" rowspan="1">VV expressing gp350</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR73">73</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Adv expressing gp350</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR77">77</xref></sup></td></tr><tr><td colspan="1" rowspan="1">gp350/gB/EBNA-2 or EBNA-3C</td><td colspan="1" rowspan="1">VV expressing gp350, gB, EBNA-2, or EBNA-3C</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR99">99</xref></sup></td></tr><tr><td colspan="1" rowspan="1">EBNA-1</td><td colspan="1" rowspan="1">Adv expressing EBNA-1 and VV-EBNA-1</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR96">96</xref></sup></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">GLA/SE</italic> glucopyranosyl lipid A incorporated into a stable emulsion, <italic toggle="yes">ISCOMs</italic> immune-stimulating complexes, <italic toggle="yes">SAF-1</italic> Syntex adjuvant formulation, <italic toggle="yes">Fc</italic> crystallizable fragment, <italic toggle="yes">&#945;DEC-205-EBNA-1</italic> C-terminus of EBNA-1 fused with DEC-205 (a human endocytic receptor), <italic toggle="yes">CTL</italic> cytotoxic T lymphocytes, <italic toggle="yes">TT</italic> tetanus toxoid, <italic toggle="yes">IFA</italic> incomplete Freund&#8217;s adjuvant, <italic toggle="yes">DCs</italic> dendritic cells, <italic toggle="yes">SAS</italic> sigma adjuvant system, <italic toggle="yes">LS</italic> lumazine synthase, <italic toggle="yes">NDV</italic> Newcastle disease virus, <italic toggle="yes">HBc149</italic> hepatitis B core antigen, <italic toggle="yes">VV</italic> vaccinia virus, <italic toggle="yes">Adv</italic> adenovirus.</p></table-wrap-foot></table-wrap></p><sec id="Sec4"><title>Vaccine candidates</title><p id="Par12">Considering the complexity of the EBV life cycle, EBV glycoproteins, lytic proteins, and latent proteins are all potential immunogens in EBV vaccine design. It is worth noting that the oncogenic potential of latent proteins should be avoided through proper modification of their immunogenic forms. It is likely that combinations of antigens will induce a more protective immune response, but much needs to be done to define the optimal selections of antigens or their combinations.</p><sec id="Sec5"><title>Vaccines using lytic glycoproteins as immunogens</title><sec id="FPar1"><title>gp350</title><p id="Par13">gp350 is the most abundant glycoprotein on the EBV envelope and most previous vaccine studies focused on this antigen<sup><xref ref-type="bibr" rid="CR55">55</xref>&#8211;<xref ref-type="bibr" rid="CR79">79</xref></sup>. The selection of an adjuvant is one of the pivotal parts to develop an effective subunit and several combinations have been tested in various models.</p><p id="Par14">Vaccines comprising monomeric gp350 (mono-gp350-based vaccines) have been combined with various adjuvants, including alum<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup>, glucopyranosyl lipid A incorporated into the stable emulsion (GLA/SE)<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>, Syntex adjuvant formulation (SAF-1)<sup><xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup>, immune-stimulating complexes (ISCOMs)<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>, Freund&#8217;s adjuvant <sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup>, and incomplete Freund&#8217;s adjuvant (IFA)<sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR67">67</xref></sup> (Table <xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par15">The immune response to monomeric gp350 has been influenced by these different adjuvants. Mono-gp350 adjuvanted with alum protected three out of five cottontop tamarins from lymphoma and reduced secretion of EBV DNA in common marmosets<sup><xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup>. Additionally, mono-gp350 adjuvanted with alum induced more robust protective responses than Freund&#8217;s adjuvant and IFA in common marmosets<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. In a different study, mono-gp350 adjuvanted with alum elicited the same antibody levels in a rabbit model compared with SAF-1<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. Cottontop tamarins inoculated with mono-gp350 and SAF-1 were protected from lymphoma (two out of three were free of lymphoma<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>; four out of four were free of lymphoma<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>). Furthermore, vaccines incorporating mono-gp350 into glycoside Quil A-based ISCOMs required a lower antigen dose to protect four out of four cottontop tamarins from tumorigenesis after EBV challenge<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. Besides, after inoculation of mono-gp350 with the Toll-like receptor 4 (TLR4) agonist GLA/SE, a gp350-specific T cell response was elicited, and anti-gp350 antibodies were detected for more than a year, indicating a durable immune response in vaccinated mice<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>. In addition, mono-gp350 adjuvanted with Freund&#8217;s adjuvant required less antigen dose and induced higher neutralizing titers than that adjuvanted with alum in rabbit<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. Finally, sera from rabbits and owl monkeys inoculated with gp350 alone could mediate antibody-dependent cellular cytotoxicity (ADCC)<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>.</p><p id="Par16">To sum up, although the various combinations with mono-gp350 were not systematically compared, they illustrate the critical role of adjuvants to address the requirements for lower gp350 antigen doses, less frequent inoculations, and durable immune responses. One study showed that levels of neutralizing antibodies do not reflect the protective effect of a vaccine in common marmosets<sup><xref ref-type="bibr" rid="CR57">57</xref></sup> while other studies emphasized the essential role of neutralizing antibodies at prevention tumor prevention in cottontop tamarins<sup><xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR61">61</xref></sup>. Among the adjuvants formulated with mono-gp350, SAF-1 seems to be better than alum to attain protection<sup><xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup>. GLA/SE is beneficial to induce cellular immune responses<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>. Importantly, even with the applications of various adjuvants, these vaccines still need to be inoculated several times in order to elicit immune responses that protect animals from lymphoma. With the development of novel adjuvants, mono-gp350-based EBV vaccines may be successful in preventing EBV infection and associated diseases.</p><p id="Par17">Sera of mice immunized with non-adjuvanted liposomes incorporating monomeric soluble gp350 (lipo-gp350) neutralize EBV infection in vitro<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>. However, multiple inoculations of lipo-gp350 adjuvanted with lipid A (fraction from <italic toggle="yes">E.coli</italic> lipopolysaccharide) induced high titers of neutralizing antibodies in mice and cottontop tamarins<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>. After 17 immunizations, cottontop tamarins vaccinated with lipo-gp350 were protected from lymphoma, while those immunized six times with lipo-gp350 still developed lymphoma<sup><xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR59">59</xref></sup>. Therefore, liposome delivery of gp350 combined with an efficient adjuvant may be another potential strategy to develop an effective EBV vaccine.</p><p id="Par18">The use of multimeric gp350 has also been explored because of its higher immunogenicity compared to monomers. Mice immunized with tetrameric gp350<sup>1&#8211;470</sup> using alum and CpG oligonucleotides (CpG ODN) as adjuvants elicited much higher anti-gp350 antibody and specific CD4<sup>+</sup> T cell responses than mice immunized with monomeric gp350<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. The enhanced immunogenicity may be due to enhanced B cell receptor (BCR) binding and signaling, vaccine uptake, or presentation and trapping by follicular dendritic cells. The first step of B cell activation is BCR recognition and cross-linking, thus, multimeric antigens are more effective because they better mimic the natural arrangement of multiple copies of the antigen on the virion surface. In addition, a heterodimeric antigen consisting of a mouse IgG2a crystallizable fragment (Fc) fragment and gp350 induced higher neutralizing antibody titers in mice compared to monomeric gp350<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>.</p><p id="Par19">As different approaches to gp350-based EBV vaccination, vaccinia virus and adenovirus were used as viral vectors to express gp350. The WR strain of vaccinia virus expressing gp350 (VV-gp350) induced humoral immune responses in rabbits, cottontop tamarins, and common marmosets<sup><xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR73">73</xref></sup>. It is remarkable that although no anti-gp350 antibodies and low levels of neutralizing antibodies were detected in cottontop tamarins inoculated with VV-gp350, three out of four animals were still free of lymphoma after an EBV challenge with a dose of 10<sup>5.3</sup> lymphocytes-transforming doses that cause tumors in 100% of unvaccinated tamarins<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. Similarly, all cottontop tamarins, which were vaccinated with a serotype 5 adenovirus expressing gp350 (Ad-gp350), were protected from lymphoma in vivo, even though their sera did not neutralize EBV in vitro<sup><xref ref-type="bibr" rid="CR77">77</xref></sup>.</p><p id="Par20">A DNA vaccine targeting antigen-presenting cells (APC) showed a good ability to elicit T-cell responses to gp350. Mice immunized with a recombinant pcDNA3.1 vector encoding gp350 induced not only gp350-specific antibodies but also cellular immune responses<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>. In a different study, sera from mice immunized with a plasmid expressing a gp350<sup>1&#8211;470</sup> tetramer delivered with the PowderJect-XR-1 system showed higher antibody titers than those immunized with monomeric gp350<sup>1&#8211;470</sup><sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. Those studies showed that nucleotide vaccines are attractive to improve immunogenicity and induce a stronger T-cell response that is crucial for killing EBV-infected cells. Note that only DNA vaccines have been studied and no data on RNA-based vaccines are currently available. mRNA vaccines for SARS-CoV-2 showed potent protective effects<sup><xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR81">81</xref></sup>. Recently, Moderna Inc. announced the initiation of a phase I study for its EBV mRNA vaccine mRNA-1189 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05164094">NCT05164094</ext-link>). The efficacy of such mRNA-based vaccines will likely influence the design of future EBV vaccines.</p><p id="Par21">Other gp350-based vaccines include nanoparticle vaccines, epitope vaccines, and VLPs. Ferritin nanoparticles self-assemble to display 24 copies of gp350 (ferritin-gp350)<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>. These nanoparticles adjuvanted with Sigma Adjuvant System (SAS) elicited neutralizing antibodies in both mice and cynomolgus macaques<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>. Additionally, the immunized mice were protected from challenges with a recombinant vaccinia virus expressing gp350<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>. Nanoparticles of lumazine synthase (LS) or I3-01 displaying gp350 domain I/II/III induced higher titers of neutralizing antibodies than the monomeric form of gp350<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>.</p><p id="Par22">Similarly, mice immunized with gp350 Cytotoxic T lymphocytes (CTL) epitopes combined with IFA and tetanus toxoid were also protected against the challenge of recombinant vaccinia virus expressing gp350<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. The data highlight the importance of gp350 CTL epitopes and suggest that such epitopes are beneficial in the design of EBV vaccines.</p><p id="Par23">Virus-like particles (VLPs) provide another attractive delivery system for EBV gp350 antigens. VLPs are multimeric self-assembled particles consisting of one or more structural proteins without a viral genome, which have no pathogenicity. Because their morphology and organization patterns are similar to natural viruses, VLPs can induce both cellular and humoral immune responses<sup><xref ref-type="bibr" rid="CR82">82</xref></sup>. Chimeric VLPs based on the self-assembling hepatitis B capsid fragment hepatitis B core antigen (HBc149) were constructed to display three immunodominant epitopes of gp350<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>. In this system, these three peptides from the receptor binding domain of gp350 induced neutralizing antibodies in mice<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>. Interestingly, the humoral immune response was highly dependent on the sequential order in which these peptides were inserted in the HBc149 backbone<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>. VLPs based on Newcastle disease virus (NDV) capsid were constructed to display the ectodomain of gp350 (NDV-VLPs-gp350). These VLPs elicited a robust and durable neutralizing antibody response in mice<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>.</p></sec><sec id="FPar2"><title>Other glycoproteins and combinations of glycoproteins</title><p id="Par24">EBV entry into target cells is a well-organized and complex process. In addition to gp350, other glycoproteins are involved in virus entry and targeted by neutralizing antibodies. Central to the process of membrane fusion is the herpesvirus core fusion apparatus comprising gB trimers and gH/gL heterodimers<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Additionally, EBV B cell tropism is determined by the expression of gp42<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. All these glycoproteins are potential antigens for vaccines aimed at neutralizing infection. Sera from rabbits inoculated with a mixture of glycoproteins prepared from the plasma membrane of EBV-positive P3HR-1 cells neutralized EBV in vitro<sup><xref ref-type="bibr" rid="CR83">83</xref></sup>. Mice immunized with an epitope-based vaccine comprising gp85 (gH) and gp350 epitopes were protected from challenges with a recombinant vaccinia virus expressing gp85 or gp350<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. Neutralizing titers of sera from rabbits immunized with trimeric or monomeric gH/gL, trimeric gB, and tetrameric gp350<sup>1&#8211;470</sup> were much higher than those elicited by monomeric gp350<sup>1&#8211;470</sup> (100-fold, 20-fold, 18-fold, and 4-fold higher, respectively)<sup><xref ref-type="bibr" rid="CR84">84</xref></sup>. Ferritin nanoparticles containing gH/gL/gp42 elicited 2.5-fold higher neutralizing antibody levels against B cells infection and 250-fold higher neutralizing antibody titers against epithelial cells infection compared to ferritin-gp350<sup><xref ref-type="bibr" rid="CR85">85</xref></sup>. In addition, nanoparticles displaying 60 copies of gH/gL instead of monomeric gH/gL induced neutralizing antibodies protected humanized mice from lethal EBV challenge<sup><xref ref-type="bibr" rid="CR86">86</xref></sup>. Besides, a pentavalent vaccine based on NDV-VLPs containing EBV gp350, gB, gp42, gH, and gL was used with alum and monophosphoryl lipid A (MPLA) as adjuvants<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>. This cocktail induced neutralizing antibodies against infection of both B and epithelial cells in vitro<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>. Moreover, gH/gL/gp42 and gH/gL ferritin nanoparticles induced neutralizing antibodies in mice, ferrets, and nonhuman primates<sup><xref ref-type="bibr" rid="CR88">88</xref></sup>. No immune competition was observed when combined with gp350D<sub>123</sub> ferritin nanoparticles<sup><xref ref-type="bibr" rid="CR88">88</xref></sup>. Besides, the passive transfer of antibodies purified from mice immunized with gH/gL/gp42&#8201;+&#8201;gp350D<sub>123</sub> or gH/gL&#8201;+&#8201;gp350D<sub>123</sub> ferritin nanoparticles protected humanized mice from EBV-associated lymphoma<sup><xref ref-type="bibr" rid="CR88">88</xref></sup>. These results clearly support the fact that gH/gL and gB are promising immunogen candidates. Recently, a clinical trial has been launched to evaluate an mRNA vaccine (mRNA-1189), which includes four mRNAs encoding gH, gL, gp42, and gp220 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05164094">NCT05164094</ext-link>). Overall, combining glycoprotein antigens is a promising approach for successful EBV vaccine development.</p></sec></sec><sec id="Sec6"><title>Vaccines using latent proteins and other lytic proteins as immunogens</title><p id="Par25">Proteins that are not involved in virus entry should also be taken into consideration to develop effective vaccines for their expression in infected cells. These targets include other proteins of the lytic cycle as well as proteins expressed in various stages of latency.</p><p id="Par26">In particular, EBNA-1 proved to be a robust immunogen. This antigen is expressed in almost all EBV-linked diseases and its role in maintaining the EBV genome in infected cells is a key factor in viral persistent infections<sup><xref ref-type="bibr" rid="CR89">89</xref></sup>. EBNA-1 can be recognized by CD4<sup>+</sup> T cells from almost all healthy carriers and EBNA-1-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells react with EBV-transformed B cells<sup><xref ref-type="bibr" rid="CR90">90</xref>&#8211;<xref ref-type="bibr" rid="CR94">94</xref></sup>. To use EBNA-1 as a vaccine, its C-terminus was fused with DEC-205 (a human endocytic receptor) and adjuvanted with poly (I:C)<sup><xref ref-type="bibr" rid="CR95">95</xref></sup>. This vaccine candidate induced robust anti-EBNA-1 CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses as well as anti-EBNA-1 IgM antibodies in humanized mice<sup><xref ref-type="bibr" rid="CR95">95</xref></sup>. A heterologous prime-boost vaccination that combined a primary immunization with a recombinant adenovirus expressing EBNA-1 and a boost with a modified vaccinia virus Ankara (MVA) expressing EBNA-1 protected mice from EBNA-1 positive lymphoma after challenge<sup><xref ref-type="bibr" rid="CR96">96</xref></sup>. Another nuclear antigen, EBNA-2 is one of the first viral proteins expressed during the initial stage of B cell immortalization<sup><xref ref-type="bibr" rid="CR97">97</xref></sup>. EBV-infected B cells are recognized by EBNA-2-specific CD8<sup>+</sup> T cells within 1-day post-infection and their proliferation can be prevented<sup><xref ref-type="bibr" rid="CR97">97</xref></sup>.</p><p id="Par27">BZLF-1 (Zta) has also been investigated as an immunogen. In a model of EBV-associated lymphoproliferative disease (LPD), survival rates of humanized mice significantly increased due to the specific CD8<sup>+</sup> T cell response induced after inoculation of dendritic cells (DCs) transfected to express BZLF-1<sup><xref ref-type="bibr" rid="CR98">98</xref></sup>. This result suggests that the BZLF-1-based vaccine could potentially prevent or delay EBV-associated diseases<sup><xref ref-type="bibr" rid="CR98">98</xref></sup>.</p></sec><sec id="Sec7"><title>Combinations of membrane glycoproteins, latent, and lytic proteins</title><p id="Par28">The above studies indicate that proteins involved in virus entry, lytic infection, as well as latency, can contribute to an effective vaccine against EBV. It is, therefore, worth considering different combinations of latent and lytic proteins to develop a comprehensive cocktail vaccine. Toward that goal, a multivalent vaccine was devised by combining recombinant vaccinia viruses, each expressing gp350, gp110, EBNA-2, or EBNA-3C<sup><xref ref-type="bibr" rid="CR99">99</xref></sup>. This cocktail induced CD4<sup>+</sup> T cell responses and antibody responses in mice, indicating that the combination of different EBV proteins into a single dose produces the desired immune response<sup><xref ref-type="bibr" rid="CR99">99</xref></sup>.</p><p id="Par29">Heterologous VLP is another platform of choice to combine various antigens. NDV-VLPs-gH/gL-EBNA-1 and NDV-VLPs-gB-LMP-2 induced potent neutralizing antibodies as well as EBV-specific cellular responses in mice<sup><xref ref-type="bibr" rid="CR100">100</xref></sup>. A different approach is to produce EBV-VLPs in non-transforming, virus-free packaging cell lines, using EBV genomes with deletions of some genes<sup><xref ref-type="bibr" rid="CR101">101</xref></sup>. For instance, EBV-VLPs lacking major oncoproteins EBNA-2, LMP-1, EBNA-3A, -B and -C, and BZLF-1 can be produced in engineered 293-VII<sup>+</sup> cells<sup><xref ref-type="bibr" rid="CR102">102</xref></sup>. Such EBV-VLPs elicited potent humoral and cellular responses in mice<sup><xref ref-type="bibr" rid="CR102">102</xref></sup>. Alternatively, EBV-VLPs with deletions of BFLF-1/BFRF-1A or of BBRF-1 induced a CD4<sup>+</sup> T cell response<sup><xref ref-type="bibr" rid="CR103">103</xref></sup>. The above EBV-VLPs usually contain many lytic proteins instead of latent proteins. Van Zyl et al.<sup><xref ref-type="bibr" rid="CR104">104</xref></sup> constructed more immunogenic particles by overexpressing EBNA-1 in producer cells. Humanized mice immunized with these EBNA-1-VLPs were successfully protected against EBV challenge<sup><xref ref-type="bibr" rid="CR104">104</xref></sup>. However, except for latent proteins, BNRF1 and viral particles can also induce genetic instability and chromosome defects in infected cells<sup><xref ref-type="bibr" rid="CR105">105</xref>,<xref ref-type="bibr" rid="CR106">106</xref></sup>. Hence, safety evaluation of genetic instability and chromosome defects is needed for VLPs generated from non-transforming, virus-free packaging cell lines.</p></sec></sec><sec id="Sec8"><title>Animal models</title><p id="Par30">The lack of suitable animal models greatly hinders the research and development of EBV vaccines. Animal models which can be used to assess the protective effect of EBV vaccine candidates after EBV challenge, include humanized mice, rabbits, as well as nonhuman primates such as rhesus macaques, owl monkeys, cottontop tamarins, and common marmosets.</p><sec id="Sec9"><title>Humanized mice</title><p id="Par31">Humanized mice are a novel model to investigate EBV infection and pathogenesis, study EBV-associated diseases as well as evaluate EBV vaccine candidates<sup><xref ref-type="bibr" rid="CR107">107</xref></sup>. Humanized mice are based on immunodeficient mice, such as non-obese diabetic mice with <italic toggle="yes">scid</italic>, <italic toggle="yes">RAG</italic>, and/or IL-2 receptor &#947; chain mutations. These mice are transplanted with human CD34<sup>+</sup> hematopoietic progenitor cells (HPCs) or peripheral blood mononuclear cells (PBMCs) from healthy donors. Infected cells in humanized mice express both latent and lytic EBV antigens after viral challenge<sup><xref ref-type="bibr" rid="CR108">108</xref></sup>. Importantly, they can develop asymptomatic EBV infections, IM-like syndromes, or tumors depending on the EBV challenge dose, thus, they are useful models to study protection against EBV pathologies<sup><xref ref-type="bibr" rid="CR108">108</xref>,<xref ref-type="bibr" rid="CR109">109</xref></sup>. EBV-specific cellular immune responses are observed in humanized mice following EBV infection and the immune responses elicited by vaccines are similar to those of humans<sup><xref ref-type="bibr" rid="CR110">110</xref>,<xref ref-type="bibr" rid="CR111">111</xref></sup>. Furthermore, the innate immunity generated by reconstituted human NK cells also plays a significant role in the control of EBV lytic infections in this model<sup><xref ref-type="bibr" rid="CR112">112</xref></sup>. However, humanized mice lack human epithelial cells, which are instrumental in the whole EBV infection cycle. Additionally, the development of &#8220;human&#8221; germinal centers and secondary lymphoid tissues is poor in this model<sup><xref ref-type="bibr" rid="CR109">109</xref>,<xref ref-type="bibr" rid="CR113">113</xref></sup>. Hence, the humoral immune responses cannot be reliably evaluated in the current humanized mice models. IgM antibody production against the viral capsid antigen BFRF-3 is detected in humanized mice<sup><xref ref-type="bibr" rid="CR114">114</xref></sup>. Therefore, humanized mouse model is more suitable to evaluate the passive protective effect of antibodies purified from immunized mice, rabbits, or nonhuman primates. Studies using humanized mice to evaluate EBV vaccines are compiled in Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Humanized mice models for EBV vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Year</th><th colspan="1" rowspan="1">Vaccine formulation and immunization route</th><th colspan="1" rowspan="1">Challenge strain</th><th colspan="1" rowspan="1">Results</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">2008</td><td colspan="1" rowspan="1"><p>&#945;DEC-205-EBNA-1(aa400-641)&#8201;+&#8201;poly(I:C)</p><p>i.p. twice at one month interval</p></td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">EBNA-1 specific T cells and anti-EBNA-1 antibodies were detected</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR95">95</xref></sup></td></tr><tr><td colspan="1" rowspan="1">2015</td><td colspan="1" rowspan="1"><p>rAd5F35/BZLF-1-transduced human DCs</p><p>i.p. once or twice at a 2-week interval</p></td><td colspan="1" rowspan="1">None<sup>A</sup></td><td colspan="1" rowspan="1">Prolonged survival to EBV-LPD</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR98">98</xref></sup></td></tr><tr><td colspan="1" rowspan="1">2018</td><td colspan="1" rowspan="1"><p>immunogenic particles containing EBNA-1&#8201;+&#8201;poly(I:C)</p><p>i.p. twice at a 4-week interval</p></td><td colspan="1" rowspan="1">B95-8</td><td colspan="1" rowspan="1">Significant protection against EBV challenge</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR104">104</xref></sup></td></tr><tr><td colspan="1" rowspan="1">2022</td><td colspan="1" rowspan="1"><p>Passive infusion of antibodies purified from mice immunized with gH/gL/gp42&#8201;+&#8201;gp350D<sub>123</sub> or gH/gL&#8201;+&#8201;gp350D<sub>123</sub> ferritin nanoparticles 20&#8201;&#181;g of mIgG per gram of mouse</p><p>i.p. at day &#8722;1, day 0, and day 1</p></td><td colspan="1" rowspan="1">B95-8</td><td colspan="1" rowspan="1">Only one of six mice in each group received immune IgG had transient low-level viremia</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR88">88</xref></sup></td></tr><tr><td colspan="1" rowspan="1">2022</td><td colspan="1" rowspan="1"><p>Passive infusion of antibodies purified from mice immunized with gH/gL 60 mer nanoparticle 500&#8201;mg of total IgG per mouse</p><p>i.p. 48&#8201;h pre EBV challenge</p></td><td colspan="1" rowspan="1">B95-8</td><td colspan="1" rowspan="1">Purified antibodies from immunized mice protected humanized mice from lethal EBV challenge</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR86">86</xref></sup></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">&#945;DEC-205-EBNA-1</italic> C-terminus of EBNA-1 fused with DEC-205 (a human endocytic receptor), <italic toggle="yes">None</italic> there is no challenge experiment. <italic toggle="yes">i.p</italic>. intraperitoneally, <italic toggle="yes">DCs</italic> dendritic cells. <italic toggle="yes">EBV-LPD</italic> EBV-associated lymphoproliferative diseases.</p><p><sup>A</sup>humanized mice reconstituted with cells from an EBV-seropositive donor was used in this study.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Rabbits</title><p id="Par32">Evidence showed that Japanese White rabbits can be persistently infected by EBV through intravenous inoculation since viral DNA and anti-EBV-VCA antibodies were both detected for 15 months<sup><xref ref-type="bibr" rid="CR115">115</xref></sup>. Notably, persistent infections were also observed following infection of New Zealand White rabbits and Japanese White rabbits via the oral route, which is also the natural infection route in humans<sup><xref ref-type="bibr" rid="CR116">116</xref>,<xref ref-type="bibr" rid="CR117">117</xref></sup>. Furthermore, cells from New Zealand White rabbits infected intravenously proliferated in vivo following immunosuppression by cyclosporine A, which is reminiscent of observations in human post-transplantation lymphoproliferative disorder (PTLD) patients<sup><xref ref-type="bibr" rid="CR118">118</xref></sup>. Together, these studies indicated that rabbit models are potential platforms for EBV vaccine evaluation.</p></sec><sec id="Sec11"><title>Nonhuman primates</title><p id="Par33">Rhesus lymphocryptovirus (rhLCV) is a homolog of EBV that only infects rhesus macaques and shares the same infectious features with EBV<sup><xref ref-type="bibr" rid="CR119">119</xref></sup>. Experimental rhLCV infection in rhesus macaque causes either asymptomatic persistent latent infection or IM-like syndrome in immunocompetent macaques. However, in immunosuppressed macaques previously infected by simian immunodeficiency virus, rhLCV infection can lead to tumor formation<sup><xref ref-type="bibr" rid="CR119">119</xref>&#8211;<xref ref-type="bibr" rid="CR121">121</xref></sup>. Differences between rhLCV and EBV cannot be ignored, however, rhLCV vaccines and challenges performed in rhesus macaques can be considered as an indirect surrogate model to assess EBV vaccines<sup><xref ref-type="bibr" rid="CR122">122</xref></sup>. Rhesus monkeys immunized with soluble rhLCV gp350 combined with alum as the adjuvant were protected against rhLCV oral challenge<sup><xref ref-type="bibr" rid="CR123">123</xref></sup>. Interestingly, 72A1, a strong neutralizing monoclonal antibody targeting EBV gp350, protected rhesus macaques from oral challenge with a recombinant rhLCV carrying EBV gp350<sup><xref ref-type="bibr" rid="CR124">124</xref></sup>. Such a chimeric virus may provide an interesting model to assess the in vivo protective effect of antibodies elicited by vaccine candidates.</p><p id="Par34">Cottontop tamarins, common marmosets, and owl monkeys can be experimentally infected by EBV and recapitulate different aspects of human disease (Table <xref rid="Tab3" ref-type="table">3</xref>). Cottontop tamarins are susceptible to experimental EBV infection and can develop malignant lymphomas after challenge with high doses of EBV<sup><xref ref-type="bibr" rid="CR125">125</xref>,<xref ref-type="bibr" rid="CR126">126</xref></sup>. Cleary and colleagues<sup><xref ref-type="bibr" rid="CR127">127</xref></sup> determined the 100% tumorigenesis dose of EBV strain B95-8 in cottontop tamarins and confirmed that tumors consisted of large-cell lymphomas with multiple copies of the EBV genome, which resembles the condition of PTLD patients. In addition, when cottontop tamarins recovered from tumors after the first challenge, cellular immune responses were observed after a second challenge, and these subjects remained healthy without any EBV-associated diseases<sup><xref ref-type="bibr" rid="CR128">128</xref></sup>. Common marmosets can be infected by either the M81 strain (derived from an NPC patient) or the B95-8 strain (derived from an IM patient)<sup><xref ref-type="bibr" rid="CR129">129</xref>&#8211;<xref ref-type="bibr" rid="CR132">132</xref></sup>. The symptoms of infected common marmosets include lymphocytosis, the production of heterophile antibodies and the long-term production of EBV-specific antibodies are similar to those in humans<sup><xref ref-type="bibr" rid="CR132">132</xref></sup>. After the EBV challenge, a persistent antibody response against EBV-VCA and early lytic proteins was observed<sup><xref ref-type="bibr" rid="CR132">132</xref></sup>. However, antibodies against EBNA-1 were not detected and there were no viral antigens in the lymphocytes of infected animals, which differs from human cases<sup><xref ref-type="bibr" rid="CR133">133</xref></sup>. In terms of pathologies, chronic infectious mononucleosis instead of LPD or lymphoma was observed in common marmosets. Owl monkeys also developed LPD after the experimental EBV challenge, and, interestingly, the EBV genome was found in a cell line established from an infected owl monkey<sup><xref ref-type="bibr" rid="CR134">134</xref>,<xref ref-type="bibr" rid="CR135">135</xref></sup>.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Outcomes of Nonhuman primate after EBV infection reflect different aspects of human diseases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Animal models</th><th colspan="1" rowspan="1">Reflection of human disease aspects</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Cottontop tamarins</td><td colspan="1" rowspan="1">(a) EBV infection; (b) Malignant lymphomas after challenge with high doses of EBV; (c) Large-cell lymphomas with multiple copies of the EBV genome (resembles the condition of PTLD patients)</td></tr><tr><td colspan="1" rowspan="1">Common marmosets</td><td colspan="1" rowspan="1">(a) EBV infection; (b) Chronic infectious mononucleosis; (c) Lymphocytosis; (d) Production of heterophile antibodies; (e) long-term production of EBV-specific antibodies</td></tr><tr><td colspan="1" rowspan="1">Owl monkeys</td><td colspan="1" rowspan="1">(a) EBV infection; (b) LPD</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">PTLD</italic> post-transplantation lymphoproliferative disorder, <italic toggle="yes">LPD</italic> lymphoproliferative disease.</p></table-wrap-foot></table-wrap></p><p id="Par35">From 1980 to 2000, various EBV vaccines were assessed in these nonhuman primate models for efficacy (Table <xref rid="Tab4" ref-type="table">4</xref>). Notably, sterilizing immunity was not achieved in any of these studies. Another limitation lies in the fact that experimental infection in nonhuman primate models is quite different from natural routes in humans. In some studies, data showed that there was no direct correlation between neutralizing antibody levels and vaccine protective effects, for some of the immunized animals with high neutralizing antibody levels still developed lymphoma after a 100% tumorigenesis virus challenge while those without high neutralizing titers free of lymphoma<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR77">77</xref></sup>. However, another study demonstrated that neutralizing antibodies is one of the key attributes of tumorigenesis prevention<sup><xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup>. Therefore, additional factors may be involved to confer complete protection, such as cellular immune responses and ADCC.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Nonhuman primate models for EBV vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Year</th><th colspan="1" rowspan="1">Animal</th><th colspan="1" rowspan="1">Vaccine formulation and immunization route</th><th colspan="1" rowspan="1">Challenge strain</th><th colspan="1" rowspan="1">Results</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1982</td><td colspan="1" rowspan="1">Owl monkey</td><td colspan="1" rowspan="1"><p>Purified gp350</p><p>Two doses</p></td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Sera had neutralizing and ADCC effects</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR76">76</xref></sup></td></tr><tr><td colspan="1" rowspan="1">1984</td><td colspan="1" rowspan="1">Cottontop tamarins</td><td colspan="1" rowspan="1"><p>Purified gp350 incorporated in liposomes&#8201;+&#8201;lipid A</p><p>i.p. six times at a 3&#8211;9-week interval</p></td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Neutralizing antibodies were detected</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR71">71</xref></sup></td></tr><tr><td colspan="1" rowspan="1">1985</td><td colspan="1" rowspan="1">Cottontop tamarins</td><td colspan="1" rowspan="1"><p>Purified gp350 incorporated in liposomes</p><p>i.p. 17 times at a 2-week interval</p></td><td colspan="1" rowspan="1">B95-8</td><td colspan="1" rowspan="1">2/2 were free of lymphoma after 100% tumorigenesis dose challenge</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR58">58</xref></sup></td></tr><tr><td colspan="1" rowspan="1">1986</td><td colspan="1" rowspan="1">Cottontop tamarins</td><td colspan="1" rowspan="1"><p>Purified gp350 incorporated into liposomes</p><p>i.p. 6 times at a 2-week interval</p></td><td colspan="1" rowspan="1">B95-8</td><td colspan="1" rowspan="1">4/4 developed lymphoma after 100% tumorigenesis dose challenge</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR59">59</xref></sup></td></tr><tr><td colspan="1" rowspan="1">1988</td><td colspan="1" rowspan="1">Cottontop tamarins</td><td colspan="1" rowspan="1"><p>Recombinant vaccinia viruses expressing gp350 (WR and Wyeth strains)</p><p>i.d. 1 or 2 times at a 2-week interval</p></td><td colspan="1" rowspan="1">B95-8</td><td colspan="1" rowspan="1">Only the recombinant WR strain protected 3/4 of animals from lymphoma after a 100% tumorigenesis dose challenge</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR73">73</xref></sup></td></tr><tr><td colspan="1" rowspan="1">1988</td><td colspan="1" rowspan="1">Cottontop tamarins</td><td colspan="1" rowspan="1"><p>Purified gp350 with ISCOMs</p><p>s.c. three times at a 2-week interval</p></td><td colspan="1" rowspan="1">B95-8</td><td colspan="1" rowspan="1">4/4 were free of lymphoma after 100% tumorigenesis dose challenge</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR72">72</xref></sup></td></tr><tr><td colspan="1" rowspan="1">1989</td><td colspan="1" rowspan="1">Common marmosets</td><td colspan="1" rowspan="1"><p>Purified gp350 with Freund&#8217;s or alum adjuvant</p><p>i.m. 3 times at a 4-week interval</p></td><td colspan="1" rowspan="1">B95-8</td><td colspan="1" rowspan="1">Alum-adsorbed antigen-induced protection against virus challenge</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR57">57</xref></sup></td></tr><tr><td colspan="1" rowspan="1">1989</td><td colspan="1" rowspan="1">Cottontop tamarins</td><td colspan="1" rowspan="1"><p>Purified gp350 with SAF-1</p><p>s.c. five times at a 2-week interval</p></td><td colspan="1" rowspan="1">B95-8</td><td colspan="1" rowspan="1">4/4 were free of lymphoma after 100% tumorigenesis dose challenge</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR70">70</xref></sup></td></tr><tr><td colspan="1" rowspan="1">1992</td><td colspan="1" rowspan="1">Cottontop tamarins</td><td colspan="1" rowspan="1"><p>recombinant gp350 with BPV&#8201;+&#8201;SAF-1 adjuvant</p><p>i.m. four times at a 10-day interval</p></td><td colspan="1" rowspan="1">B95-8</td><td colspan="1" rowspan="1">2/3 was free of lymphoma after 100% tumorigenesis dose challenge</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR61">61</xref></sup></td></tr><tr><td colspan="1" rowspan="1">1993</td><td colspan="1" rowspan="1">Cottontop tamarins</td><td colspan="1" rowspan="1"><p>Recombinant adenovirus (serotype 5) expressing gp350</p><p>i.m. three times at 0-5-13 weeks</p></td><td colspan="1" rowspan="1">B95-8</td><td colspan="1" rowspan="1">4/4 were free of lymphoma after 100% tumorigenesis dose challenge</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR77">77</xref></sup></td></tr><tr><td colspan="1" rowspan="1">1994</td><td colspan="1" rowspan="1">Cottontop tamarins</td><td colspan="1" rowspan="1"><p>recombinant gp350 with BPV&#8201;+&#8201;alum</p><p>i.m. four times at a 4-week interval</p></td><td colspan="1" rowspan="1">B95-8</td><td colspan="1" rowspan="1">3/5 were free of lymphoma after 100% tumorigenesis dose challenge</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR60">60</xref></sup></td></tr><tr><td colspan="1" rowspan="1">1996</td><td colspan="1" rowspan="1">Common marmosets</td><td colspan="1" rowspan="1"><p>Recombinant vaccinia virus expressing gp350</p><p>i.d. twice at a 5-week interval</p></td><td colspan="1" rowspan="1">M81</td><td colspan="1" rowspan="1">Replication of the challenge virus was decreased</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR69">69</xref></sup></td></tr><tr><td colspan="1" rowspan="1">1998</td><td colspan="1" rowspan="1">Common marmosets</td><td colspan="1" rowspan="1"><p>recombinant gp350 with BPV&#8201;+&#8201;alum</p><p>i.m. three times at a 4-week interval</p></td><td colspan="1" rowspan="1">M81</td><td colspan="1" rowspan="1">Replication of the challenge virus was decreased</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR55">55</xref></sup></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">None</italic> there is no challenge experiment, <italic toggle="yes">ADCC</italic> antibody-dependent cell-mediated cytotoxicity. <italic toggle="yes">ISCOMs</italic> immune stimulation complexes, <italic toggle="yes">SAF-1</italic> Syntex adjuvant formulation, <italic toggle="yes">BPV</italic> bovine papillomavirus expression vector, <italic toggle="yes">i.p</italic>. intraperitoneally, <italic toggle="yes">i.d</italic>. intradermally, <italic toggle="yes">s.c</italic>. subcutaneously, <italic toggle="yes">i.m</italic>. intramuscularly.</p></table-wrap-foot></table-wrap></p><p id="Par36">Finally, one should note that nonhuman primates are expensive and not necessarily amenable to large and preliminary studies of vaccine candidates. In addition, specific models for EBV, such as marmosets and owl monkeys, are rare and not readily accessible. Cottontop tamarins are not available since they are an endangered species.</p></sec></sec><sec id="Sec12"><title>Clinical trials</title><p id="Par37">From 1990 onwards, seven human clinical trials have been launched utilizing EBV gp350 or EBNA-3. For instance, Gu et al.<sup><xref ref-type="bibr" rid="CR136">136</xref></sup> utilized a live recombinant vaccinia virus (Tien Tan strain) expressing gp350 to immunize three groups of volunteers, including 11 adults (EBV seropositive and vaccinia seropositive), six juveniles (EBV seropositive and vaccinia seronegative), and 19 infants (EBV seronegative and vaccinia seronegative). In the adult group, antibody titers against EBV did not change after inoculation, while neutralizing antibody titers increased in young children and infants. Three out of nine infants still became naturally infected by EBV later. Meanwhile, ten out of ten control infants also became naturally infected. Moutschen and colleagues<sup><xref ref-type="bibr" rid="CR137">137</xref></sup> compared three vaccine formulations (recombinant gp350 alone, recombinant gp350 with alum, or recombinant gp350 with AS04) in seronegative and seropositive youths. All formulations were safe and well-tolerated. The formulation containing gp350 alone showed the weakest immunogenicity. Despite the detection of neutralizing antibodies and cellular immune responses, some subjects still became naturally infected. These observations are partly consistent with results obtained in common marmosets and cottontop tamarins, as discussed above. A phase II trial enrolled 181 seronegative young volunteers to test an EBV vaccine formulated with recombinant EBV gp350 and AS04 as an adjuvant<sup><xref ref-type="bibr" rid="CR138">138</xref></sup>. Although anti-gp350 antibodies were detected over 18 months, this vaccine only prevented IM but not asymptomatic EBV infection. Another phase I trial recruited children with chronic kidney disease waiting for organ transplantation<sup><xref ref-type="bibr" rid="CR139">139</xref></sup>. After inoculating two different doses (12.5 and 25&#8201;&#956;g) of recombinant gp350 with alum, specific IgGs were found in all subjects. However, neutralizing antibodies were only detected in 1/4 of subjects who received the low dose and in 3/9 of subjects who received the high dose. Nevertheless, titers dropped quickly and vaccination did not affect the post-transplant immune condition of these children. Recently, a phase I clinical trial for a gp350-ferritin nanoparticle vaccine started to recruit subjects to evaluate vaccine safety and immunogenicity (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04645147">NCT04645147</ext-link>). Another phase I clinical trial for an mRNA-based vaccine (mRNA-1189) containing four mRNA encoding gH, gL, gp42, and gp220 has been launched to evaluate to safety and tolerability of EBV mRNA vaccine in healthy adults ages 18 to 30 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05164094">NCT05164094</ext-link>).</p><p id="Par38">Aside from glycoprotein-based vaccines, an EBNA-3 epitope-based vaccine was tested in 14 HLA B*0801-positive EBV-seronegative adults in a phase I trial<sup><xref ref-type="bibr" rid="CR140">140</xref></sup>. This vaccine consisted of an EBNA-3 CD8<sup>+</sup> epitope (FLRGRAYGL) combined with tetanus toxoid as CD4<sup>+</sup> T cell helper and Montanide ISA 720 as the adjuvant. The vaccine proved to be safe and epitope-specific responses were observed, however, some immunized subjects seroconverted asymptomatically.</p></sec></sec><sec id="Sec13"><title>What can we do?</title><p id="Par39">Previous clinical trials failed to generate sterile immunity. However, all these efforts generated valuable information but also identified many barriers that need to be overcome to develop an effective EBV vaccine. Not only EBV has a complicated life cycle involving numerous proteins, but it also displays two distinct tropisms. Thus, the selection and design of the immunogen are still the key parts of EBV vaccine development. First of all, to improve current designs, T-cell epitopes should be taken into consideration. The balance of cellular and humoral immune responses is essential for an ideal vaccine, according to the previously successful herpesvirus vaccine against VZV<sup><xref ref-type="bibr" rid="CR141">141</xref></sup>. Induction and evaluation of cellular immune responses will be necessary for novel EBV vaccine studies. Moreover, the rational optimization of immunogen combinations needs to be undertaken. Particle-based delivery systems and efficient modern adjuvants will help to improve immunogenicity, extend the duration of immune responses and reduce the inoculation doses. In addition, heterologous prime-boost immunization and induction of mucosal immunity are also promising. Finally, antibody-guided vaccine design will be worth trying according to the lessons learned from RSV and HIV vaccine studies<sup><xref ref-type="bibr" rid="CR142">142</xref></sup>. We will briefly discuss these aspects.</p><sec id="Sec14"><title>Immunogen design is the key part of vaccine development</title><p id="Par40">An effective vaccine against a human herpesvirus is Shingrix<sup>TM</sup> (GSK), which consists in glycoprotein E as the antigen and AS01<sub>B</sub> as the adjuvant. This vaccine induces potent humoral and cellular immune responses, and successfully prevents shingles in the elderly<sup><xref ref-type="bibr" rid="CR141">141</xref>,<xref ref-type="bibr" rid="CR143">143</xref></sup>. The cellular immune response induced by Shingrix<sup>TM</sup> plays a crucial role in disease prevention. It changes the paradigm that a robust humoral immune response could be sufficient for prophylactic vaccines against herpesviruses. Similarly, induction of T cell immune response is also essential and important for SARS-CoV-2 vaccine development<sup><xref ref-type="bibr" rid="CR144">144</xref></sup>. Hence, T cell epitopes should be included for the balance of cellular and humoral immune response required from an effective EBV vaccine.</p><p id="Par41">This realization is supported by data showing that immunized cottontop tamarins with high neutralizing antibodies titers can still develop lymphomas, indicating that induction of neutralizing antibodies alone is insufficient for disease prevention<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR77">77</xref></sup>. Cytotoxic and helper T-cell responses play a significant role in viral infection and disease prevention. Helper CD4<sup>+</sup> T cells are essential for B cell and CD8<sup>+</sup> T cell activation by providing secondary signals (e.g., CD28-B7) and cytokines secretion, respectively. In turn, cytokines secretion of CD4<sup>+</sup> T cells determines the types of antibodies produced. Cytokines secreted by Th1 cells (e.g., IFN-&#947;) are helpful to produce IgG2a and IgG3 in mice or IgG1 in humans, while Th2 cytokines (e.g., IL-4) preferentially induce IgG1 and IgE in mice or IgG2 in humans<sup><xref ref-type="bibr" rid="CR145">145</xref></sup>. CD8<sup>+</sup> T and CD4<sup>+</sup> T cells are especially important to kill infected cells<sup><xref ref-type="bibr" rid="CR146">146</xref>,<xref ref-type="bibr" rid="CR147">147</xref></sup>. Indeed, the CD8<sup>+</sup> T cell response is the predominant response for eliminating EBV-infected cells during lytic and latent infections<sup><xref ref-type="bibr" rid="CR148">148</xref></sup>. The important roles of T cells in controlling EBV infection warrant the inclusion of T cell epitopes in future EBV vaccines. Taylor et al. summarized the T cell epitopes of almost all EBV proteins, which provides a valuable resource to contribute to the design of future EBV vaccine candidates<sup><xref ref-type="bibr" rid="CR149">149</xref></sup>.</p><p id="Par42">Although there were strong justifications for using gp350, this limited antigen selection is likely one of the reasons for the failure to generate a sterile immunity in previous clinical trials. The EBV infection process is complicated and various glycoproteins (gp350, gH/gL, gp42, and gB for B cell infection and BMRF2, gH/gL, and gB for epithelial cell infection) are involved in EBV entry<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Anti-gHgL antibodies appear more effective since they neutralize ~75% of epithelial cell infection, while anti-gp350 antibodies neutralize ~57% of B cell infection<sup><xref ref-type="bibr" rid="CR85">85</xref></sup>. Recent studies showed that gH/gL and gB elicited more potent neutralizing antibodies than monomeric gp350<sup>1&#8211;470</sup>, and ferritin-gH/gL/gp42 induced much higher neutralizing antibody titers compared to ferritin-gp350<sup><xref ref-type="bibr" rid="CR84">84</xref>,<xref ref-type="bibr" rid="CR85">85</xref></sup>. Additionally, passive transfer of antibodies induced by nanoparticles displaying 60 copies of gH/gL, gH/gL/gp42&#8201;+&#8201;gp350D123, or by gH/gL&#8201;+&#8201;gp350D123 ferritin nanoparticles protected humanized mice from EBV-associated lymphoma<sup><xref ref-type="bibr" rid="CR86">86</xref>,<xref ref-type="bibr" rid="CR88">88</xref></sup>. Hence, gH/gL, gp42, and gB are effective and promising antigens for the development of prophylactic vaccines to be tested in clinical trials. Although the improved design may enhance gp350 immunogenicity, we believe that prophylactic vaccines with broader antigen spectra are more likely to be successful.</p><p id="Par43">To broaden the spectrum of B cell and T cell epitopes, it is worth combining glycoproteins, latent and other lytic proteins into a single dose. Previous preclinical and clinical studies focusing on gp350 have been unsatisfactory, thus, other entry glycoproteins must be considered to enhance the production of neutralizing antibodies. In addition to well-characterized entry glycoproteins, the role of several membrane glycoproteins remains unknown, such as gp150 or gp78<sup><xref ref-type="bibr" rid="CR150">150</xref></sup>, may eventually contribute to vaccine development. Besides, UV-inactivated EBV, used as a positive control in various experiments, elicited better neutralizing responses than NDV-based VLPs<sup><xref ref-type="bibr" rid="CR75">75</xref>,<xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR100">100</xref></sup>. Hence, including more potential antigens in the appropriate vector will be crucial for the rational design of multivalent vaccines. However, it is important to note that not all formulations are effective and some even produce unanticipated effects. For example, sera from mice inoculated with both VLPs-gH/gL-EBNA-1 and VLPs-gB-LMP-2 led to increased EBV infection of epithelial cells rather than neutralizing infection as expected<sup><xref ref-type="bibr" rid="CR100">100</xref></sup>. How to design the combination of EBV proteins is still a key issue.</p></sec><sec id="Sec15"><title>Heterologous prime-boost approaches</title><p id="Par44">The vaccination prime-boost strategy is also important for vaccine efficiency. Heterologous prime-boost strategies were shown to be more immunogenic than homologous prime-boost approaches for HIV, herpes simplex virus type 2 (HSV-2), influenza, malaria, and tuberculosis<sup><xref ref-type="bibr" rid="CR151">151</xref></sup>. Clinical trials for heterologous prime-boost SARS-CoV-2 vaccines are underway<sup><xref ref-type="bibr" rid="CR152">152</xref></sup>. Examples of HIV vaccines have adopted &#8220;DNA prime-protein boost&#8221; strategies, which were able to induce both humoral and cellular immune responses<sup><xref ref-type="bibr" rid="CR153">153</xref>&#8211;<xref ref-type="bibr" rid="CR155">155</xref></sup>. A &#8220;DNA prime-viral vector boost&#8221; formulation against HIV has also been evaluated for its ability to induce cellular immune responses<sup><xref ref-type="bibr" rid="CR156">156</xref>,<xref ref-type="bibr" rid="CR157">157</xref></sup>. A &#8220;DNA prime-protein boost&#8221; approach for HSV-2 induced potent antibodies and both Th1 and Th2 immune responses<sup><xref ref-type="bibr" rid="CR158">158</xref></sup>. An EBNA-1-based vaccine has been proven to be effective through an &#8220;EBNA-1-expressing adenovirus prime-EBNA-1-encoding MVA boost&#8221; strategy<sup><xref ref-type="bibr" rid="CR96">96</xref></sup>. Experience from other enveloped viruses clearly indicates that a heterologous prime-boost strategy should be envisaged in the development of vaccines against EBV glycoproteins.</p></sec><sec id="Sec16"><title>Mucosal immunity</title><p id="Par45">The mucosal immune response has to be considered an important aspect of the prevention of EBV infection since EBV primary infection occurs at oropharynx sites<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Vaccines designed to increase mucosal immunity are desirable to protect against EBV infection. Induction of IgA and tissue-resident T cells should be targeted and assessed in trials of EBV vaccines. Oral or intranasal immunizations are particularly effective at inducing mucosal immunity compared to injectable vaccines. Currently, the licensed mucosal vaccines comprise inactivated or attenuated viruses administrated orally or intranasally<sup><xref ref-type="bibr" rid="CR159">159</xref></sup>. An inhaled SARS-CoV-2 vaccine (adenovirus type 5 vector), Convidecia Air<sup>TM</sup>, has been approved for Emergency Use Authorization as a booster dose<sup><xref ref-type="bibr" rid="CR160">160</xref></sup>. A series of studies provide ample evidence supporting the use of intranasal and oral vaccines to trigger robust mucosal immune responses. Hence, oral or intranasal immunizations with the appropriate EBV antigens should be considered. For instance, an inactivated virus formulation could be developed as the main vaccine or as a booster after injectable vaccines.</p></sec><sec id="Sec17"><title>Particle-based vaccine is a promising field</title><p id="Par46">Given that the immunogenicity of subunit and epitope vaccines has been usually insufficient, particles such as VLPs, protein scaffold nanoparticles, and polymer-based nanoparticles have been investigated. This approach is generally beneficial to enhance antigen immunogenicity since particles more closely mimic the characteristics of pathogens<sup><xref ref-type="bibr" rid="CR161">161</xref></sup>.</p><p id="Par47">VLPs are most similar to native viruses and have been used as immunogens in licensed HPV, HBV, and HEV vaccines<sup><xref ref-type="bibr" rid="CR162">162</xref></sup>. VLPs are promising EBV vaccine candidates due to their high immunogenicity and their ability to induce potent humoral and cellular immune responses simultaneously, even without an adjuvant. In addition, VLPs can be designed to present various antigens or could be combined in vaccine formulations to expand the antigenic spectrum. As described above, protein scaffold-based nanoparticles, including ferritin, LS-, and I3-01 are promising to present EBV glycoproteins since they can induce much stronger immune responses than the soluble forms of the antigen<sup><xref ref-type="bibr" rid="CR65">65</xref>,<xref ref-type="bibr" rid="CR66">66</xref>,<xref ref-type="bibr" rid="CR85">85</xref></sup>.</p><p id="Par48">Polymer-based nanoparticle delivery systems are highly versatile. They can be prepared with various materials such as chitosan, polyanhydrides, lactic acid, and poly (lactic-co-glycolic acid), for instance. Those nanoparticles can accumulate into lymph nodes and enhance antigen and adjuvant uptake by APCs depending on their sizes, surface charge, shapes, and hydrophobicity<sup><xref ref-type="bibr" rid="CR163">163</xref>&#8211;<xref ref-type="bibr" rid="CR166">166</xref></sup>. Additionally, polymers can protect antigens from degradation before uptake into target cells. Therefore, polymer-based nanoparticle vaccines can simultaneously induce cellular and humoral immune responses and reduce side effects (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Under ideal conditions, most nanoparticles are delivered to lymph nodes, where they effectively elicit robust humoral and cellular immune responses through enhanced uptake by APCs, promotion of BCR cross-linkage, as well as antigen cross-presentation (Fig. 2). Studies of nanoparticle vaccine against hand-foot-and-mouth disease or influenza, demonstrated the potential of polymer-based nanoparticles<sup><xref ref-type="bibr" rid="CR167">167</xref>,<xref ref-type="bibr" rid="CR168">168</xref></sup>. This approach exhibits the most advantages considered critical for the design of EBV vaccines.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Nanoparticle delivery system.</title><p><bold>a</bold> Nanoparticle vaccine delivery systems can protect antigens from enzymatic degradation. <bold>b</bold> Depending on the size of the nanoparticles, they can be passively delivered to lymph nodes and enhance antigen-presenting cells (APCs) to take up and present antigens. <bold>d</bold> Hence, germinal center (GC) formation is enhanced. <bold>c</bold>, <bold>e</bold>&#8211;<bold>h</bold> Nanoparticle vaccine delivery systems can induce cellular and humoral immune responses simultaneously with minimum side effects. <bold>i</bold> Besides, nanoparticle vaccine delivery systems can improve the levels of antigen-specific memory T cells and B cells. The figure was made from Biorender.com.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2655" position="float" orientation="portrait" xlink:href="41541_2022_587_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec18"><title>Application of modern adjuvants can enhance immune responses to EBV antigens</title><p id="Par49">Adjuvant selection is an important component of vaccine formulation since it affects the number of immunization and doses of antigens needed to obtain a protective immune response<sup><xref ref-type="bibr" rid="CR169">169</xref>,<xref ref-type="bibr" rid="CR170">170</xref></sup>.</p><p id="Par50">Many adjuvants have been approved (such as Alum, MF59, IFA, AS04, AS03, AS01b, CpG ODN, and IMQ) or are currently being tested in clinical trials (such as flagellin, Matrix-M, GLA-SE, ISCOMs, and AS02). A key role of traditional adjuvants is to build an antigen depot and improve the exposure time of the antigen. Modern adjuvants, such as agonizts of pattern recognition receptors (PRRs), concentrate on the activation of innate immunity. In the presence of PRR agonizts, APCs are activated to aid both cellular and humoral immune responses. Some TLR agonizts also interact directly with B cells and provide the co-stimulatory signals to activate T cells<sup><xref ref-type="bibr" rid="CR171">171</xref>,<xref ref-type="bibr" rid="CR172">172</xref></sup>. MPLA, an agonist of TLR4, induces Th1 and Th2 responses, while CpG ODN, an agonist of TLR9, is biased to induce a Th1-dominant response<sup><xref ref-type="bibr" rid="CR173">173</xref></sup>. The combination of PRRs agonizts and nano delivery systems to form nano-adjuvant is also a promising approach. For example, the AS01<sub>B</sub> adjuvant combines liposome as the delivery system and MPLA (TLR4 agonist) as the stimulating agent<sup><xref ref-type="bibr" rid="CR174">174</xref></sup>. Shingrix<sup>TM</sup>, which effectively prevents shingles in the elderly, is an example of a vaccine using AS01<sub>B</sub><sup><xref ref-type="bibr" rid="CR141">141</xref>,<xref ref-type="bibr" rid="CR143">143</xref></sup>. The application of the proper adjuvant or adjuvant system will greatly influence the success of subunit- and epitope-based vaccines against EBV.</p></sec><sec id="Sec19"><title>Antibody-guided vaccine design</title><p id="Par51">Finally, antibody-guided vaccine design is an innovative way to develop vaccines<sup><xref ref-type="bibr" rid="CR142">142</xref></sup>. Briefly, vaccine candidates are developed based on information obtained from the characterization of effectively neutralizing antibodies and their epitopes. The availability of neutralizing antibody libraries against corresponding antigens facilitates this approach. Relevant current examples of this strategy are found in vaccines targeting viral fusion proteins. The structure of human respiratory syncytial virus (RSV) pre-fusion F protein, together with analyses of neutralizing antibody complex, led to the design of stable pre-fusion F protein vaccines. This approach led to the development of an RSV vaccine candidate, which proved to elicit neutralizing antibodies<sup><xref ref-type="bibr" rid="CR175">175</xref>,<xref ref-type="bibr" rid="CR176">176</xref></sup>. This approach was also instrumental in designing RNA vaccines against SARS-CoV-2 expressing a stable pre-fusion form of the viral spike, which is the major target of most potent neutralizing antibodies<sup><xref ref-type="bibr" rid="CR177">177</xref>,<xref ref-type="bibr" rid="CR178">178</xref></sup>. These advances open exciting prospects for vaccines targeting EBV gB and available technologies must be used to determine the pre-fusion form of gB as the main goal of structure-based vaccine design.</p><p id="Par52">Many EBV-specific monoclonal antibodies have been isolated and characterized. Thus, the tools are available to rationally design EBV vaccines according to neutralizing epitopes recognized by these antibodies<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR179">179</xref>&#8211;<xref ref-type="bibr" rid="CR182">182</xref></sup>.</p></sec></sec><sec id="Sec20" sec-type="conclusion"><title>Conclusion</title><p id="Par53">EBV, as the first identified human oncogenic virus, causes a heavy health burden worldwide. It is imperative to develop an effective vaccine against EBV infection and EBV-associated diseases. Currently, none of the vaccine candidates are approved for clinical use, despite multiple attempts to develop an effective vaccine. Subunit vaccines, epitope vaccines, DNA vaccines, protein scaffold-based vaccines, viral vector vaccines, VLPs, and DC vaccines, all generated important information but generally failed to induce the required level of protection. Suitable animal models also need to be improved to study protection. Humanized mice, rabbits, rhesus macaques, and common marmosets are the most common animal models. However, each one of them has obvious limitations (as discussed above).</p><p id="Par54">In human clinical trials, all vaccine candidates failed to prevent EBV infection. Induction of sterile immunity significantly correlates with a reduction of EBV-associated diseases. Hence, the ultimate goal of researchers is still to generate sterile immunity. Current efforts focus on antigen selection, combination, and design to improve the efficiency of vaccines. It is worth trying to develop a vaccine using new strategies for na&#239;ve pediatric populations to prevent the initial EBV infection. However, induction of sterile immunity may not be the only standard to evaluate the success of EBV vaccines. Preventing EBV-associated disease occurrence rather than EBV infection remains a valuable outcome when completely preventing EBV infection is not achieved. Vaccination with recombinant EBV gp350 adjuvanted with AS04 reduced the incidence of IM in seronegative subjects<sup><xref ref-type="bibr" rid="CR138">138</xref></sup>. The incidence of HL and MS may be decreased accordingly<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>. Vaccination to reduce the incidence and severity of EBV-associated diseases is a valuable goal. Such goals were also established to evaluate the efficacy of SARS-CoV-2 vaccines in reducing symptomatic COVID-19<sup><xref ref-type="bibr" rid="CR183">183</xref>&#8211;<xref ref-type="bibr" rid="CR185">185</xref></sup>. Long-term clinical trials will be needed to assess the ability of the EBV vaccine to limit EBV-related diseases, in particular malignancies. Vaccination may also induce more potent cellular immune responses to control EBV reactivation in infected individuals<sup><xref ref-type="bibr" rid="CR148">148</xref></sup>. Thus a vaccine that limits reactivation frequency and severity will have a valuable protective effect on infected individuals. This has been appreciated in the VZV vaccine Shingrix<sup>TM</sup> (GSK), which successfully protects latently infected individuals from shingles<sup><xref ref-type="bibr" rid="CR141">141</xref>,<xref ref-type="bibr" rid="CR143">143</xref></sup>. EBV latent proteins and reactivation events are tightly associated with EBV-associated malignancies<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>. Hence, vaccination of infected populations has the potential to reduce EBV-associated diseases burdens. In particular, the population of south China, which is at high risk of developing nasopharyngeal carcinoma, will benefit greatly from such vaccination<sup><xref ref-type="bibr" rid="CR186">186</xref></sup>.</p><p id="Par55">Besides, delayed infection may occur due to the non-sterile vaccination. As discussed above, one consequence of a delayed infection after vaccination is that the infection will not cause diseases anymore, or reduce the severity of diseases. From the public health point of view, this would be a desirable outcome of vaccination greatly. However, whether the incidence of EBV-linked malignancies or autoimmune response can be reduced remains unclear. As observed in SARS-CoV-2 vaccination and repeated infection, the delayed infection of the Wuhan strain or other variants of concern also boosted immune responses<sup><xref ref-type="bibr" rid="CR187">187</xref></sup>. Hence, it is possible that a delayed infection, whether successful or not, may also boost anti-EBV immune responses, thereby reinforcing the individual&#8217;s protection.</p><p id="Par56">Induction of robust, long-term, and balanced humoral and cellular immune responses should remain the primary goal in the development of a protective EBV vaccine. The antigen spectrum, the immunogenicity of selected antigens, and the breadth of immune responses are the key issues to achieve this goal. Over the years, immunogen selection has changed from glycoproteins, especially gp350, to a more extensive range, including lytic and latent proteins. The identification and characterization of B and T cell epitopes of EBV protein help to further optimize immunogen design. Nanoparticle-based systems showed potential for vaccine development and novel adjuvant formulations are promising to increase immunogenicity. In addition, antibody-guided vaccine design provides a framework to improve EBV vaccine development based on the knowledge of EBV-neutralization acquired over many years.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Ling Zhong, Claude Krummenacher.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by a grant from the National Natural Science Foundation of China (81702001 to X.Z. and 81872228 to M.X.).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>L.Z., C.K., W.Z., J.H., Q.F., Y.C., Q.Z., M-S.Z., Y-X.Z., M.X., and X.Z. wrote the manuscript. All authors read and approved the final manuscript.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par57">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epstein</surname><given-names>MA</given-names></name><name name-style="western"><surname>Achong</surname><given-names>BG</given-names></name><name name-style="western"><surname>Barr</surname><given-names>YM</given-names></name></person-group><article-title>Virus particles in cultured lymphoblasts from Burkitt&#8217;s lymphoma</article-title><source>Lancet</source><year>1964</year><volume>1</volume><fpage>702</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(64)91524-7</pub-id><pub-id pub-id-type="pmid">14107961</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baer</surname><given-names>R</given-names></name><etal/></person-group><article-title>DNA sequence and expression of the B95-8 Epstein-Barr virus genome</article-title><source>Nature</source><year>1984</year><volume>310</volume><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1038/310207a0</pub-id><pub-id pub-id-type="pmid">6087149</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Structures of capsid and capsid-associated tegument complex inside the Epstein-Barr virus</article-title><source>Nat. Microbiol.</source><year>2020</year><volume>5</volume><fpage>1285</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0758-1</pub-id><pub-id pub-id-type="pmid">32719506</pub-id><pub-id pub-id-type="pmcid">PMC7546529</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>CryoEM structure of the tegumented capsid of Epstein-Barr virus</article-title><source>Cell Res.</source><year>2020</year><volume>30</volume><fpage>873</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0363-0</pub-id><pub-id pub-id-type="pmid">32620850</pub-id><pub-id pub-id-type="pmcid">PMC7608217</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Straus</surname><given-names>SE</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>JI</given-names></name><name name-style="western"><surname>Tosato</surname><given-names>G</given-names></name><name name-style="western"><surname>Meier</surname><given-names>J</given-names></name></person-group><article-title>NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management</article-title><source>Ann. Intern Med.</source><year>1993</year><volume>118</volume><fpage>45</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-118-1-199301010-00009</pub-id><pub-id pub-id-type="pmid">8380053</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>JI</given-names></name></person-group><article-title>Epstein-Barr virus infection</article-title><source>N. Engl. J. Med</source><year>2000</year><volume>343</volume><fpage>481</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1056/NEJM200008173430707</pub-id><pub-id pub-id-type="pmid">10944566</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sathiyamoorthy</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Longnecker</surname><given-names>R</given-names></name><name name-style="western"><surname>Jardetzky</surname><given-names>TS</given-names></name></person-group><article-title>The COMPLEXity in herpesvirus entry</article-title><source>Curr. Opin. Virol.</source><year>2017</year><volume>24</volume><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2017.04.006</pub-id><pub-id pub-id-type="pmid">28538165</pub-id><pub-id pub-id-type="pmcid">PMC8601108</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>N</given-names></name><name name-style="western"><surname>Hutt-Fletcher</surname><given-names>LM</given-names></name></person-group><article-title>Epstein-Barr virus enters B cells and epithelial cells by different routes</article-title><source>J. Virol.</source><year>1992</year><volume>66</volume><fpage>3409</fpage><lpage>3414</lpage><pub-id pub-id-type="doi">10.1128/jvi.66.6.3409-3414.1992</pub-id><pub-id pub-id-type="pmid">1316456</pub-id><pub-id pub-id-type="pmcid">PMC241121</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nemerow</surname><given-names>GR</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>NR</given-names></name></person-group><article-title>Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process</article-title><source>Virology</source><year>1984</year><volume>132</volume><fpage>186</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(84)90102-8</pub-id><pub-id pub-id-type="pmid">6320532</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogembo</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor</article-title><source>Cell Rep.</source><year>2013</year><volume>3</volume><fpage>371</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.01.023</pub-id><pub-id pub-id-type="pmid">23416052</pub-id><pub-id pub-id-type="pmcid">PMC3633082</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Young, K. A., Chen, X. S., Holers, V. M. &amp; Hannan, J. P. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21. <italic toggle="yes">J. Biol. Chem.</italic><bold>282</bold>, 36614&#8211;36625 (2007).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M706324200</pub-id><pub-id pub-id-type="pmid">17925391</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>KA</given-names></name><name name-style="western"><surname>Herbert</surname><given-names>AP</given-names></name><name name-style="western"><surname>Barlow</surname><given-names>PN</given-names></name><name name-style="western"><surname>Holers</surname><given-names>VM</given-names></name><name name-style="western"><surname>Hannan</surname><given-names>JP</given-names></name></person-group><article-title>Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>11217</fpage><lpage>11227</lpage><pub-id pub-id-type="doi">10.1128/JVI.01673-08</pub-id><pub-id pub-id-type="pmid">18786993</pub-id><pub-id pub-id-type="pmcid">PMC2573242</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanner</surname><given-names>J</given-names></name><name name-style="western"><surname>Weis</surname><given-names>J</given-names></name><name name-style="western"><surname>Fearon</surname><given-names>D</given-names></name><name name-style="western"><surname>Whang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kieff</surname><given-names>E</given-names></name></person-group><article-title>Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis</article-title><source>Cell</source><year>1987</year><volume>50</volume><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(87)90216-9</pub-id><pub-id pub-id-type="pmid">3036369</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sathiyamoorthy</surname><given-names>K</given-names></name><etal/></person-group><article-title>Assembly and architecture of the EBV B cell entry triggering complex</article-title><source>PLoS Pathog.</source><year>2014</year><volume>10</volume><fpage>e1004309</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1004309</pub-id><pub-id pub-id-type="pmid">25144748</pub-id><pub-id pub-id-type="pmcid">PMC4140853</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sathiyamoorthy</surname><given-names>K</given-names></name><etal/></person-group><article-title>Structural basis for Epstein-Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>13557</fpage><pub-id pub-id-type="doi">10.1038/ncomms13557</pub-id><pub-id pub-id-type="pmid">27929061</pub-id><pub-id pub-id-type="pmcid">PMC5155155</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohl</surname><given-names>BS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Longnecker</surname><given-names>R</given-names></name></person-group><article-title>Gammaherpesvirus entry and fusion: A tale how two human pathogenic viruses enter their host cells</article-title><source>Adv. Virus Res.</source><year>2019</year><volume>104</volume><fpage>313</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/bs.aivir.2019.05.006</pub-id><pub-id pub-id-type="pmid">31439152</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohl</surname><given-names>BS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Sathiyamoorthy</surname><given-names>K</given-names></name><name name-style="western"><surname>Jardetzky</surname><given-names>TS</given-names></name><name name-style="western"><surname>Longnecker</surname><given-names>R</given-names></name></person-group><article-title>Structural and mechanistic insights into the tropism of Epstein-Barr virus</article-title><source>Mol. Cells</source><year>2016</year><volume>39</volume><fpage>286</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.14348/molcells.2016.0066</pub-id><pub-id pub-id-type="pmid">27094060</pub-id><pub-id pub-id-type="pmcid">PMC4844934</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus</article-title><source>Nat. Microbiol.</source><year>2018</year><volume>3</volume><fpage>172</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1038/s41564-017-0081-7</pub-id><pub-id pub-id-type="pmid">29292384</pub-id><pub-id pub-id-type="pmcid">PMC5972547</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry</article-title><source>Nat. Microbiol</source><year>2018</year><volume>3</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-017-0080-8</pub-id><pub-id pub-id-type="pmid">29292383</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chesnokova</surname><given-names>LS</given-names></name><name name-style="western"><surname>Hutt-Fletcher</surname><given-names>LM</given-names></name></person-group><article-title>Fusion of Epstein-Barr virus with epithelial cells can be triggered by alphavbeta5 in addition to alphavbeta6 and alphavbeta8, and integrin binding triggers a conformational change in glycoproteins gHgL</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>13214</fpage><lpage>13223</lpage><pub-id pub-id-type="doi">10.1128/JVI.05580-11</pub-id><pub-id pub-id-type="pmid">21957301</pub-id><pub-id pub-id-type="pmcid">PMC3233123</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>D</given-names></name><etal/></person-group><article-title>Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>11036</fpage><lpage>11041</lpage><pub-id pub-id-type="doi">10.1073/pnas.1513359112</pub-id><pub-id pub-id-type="pmid">26290577</pub-id><pub-id pub-id-type="pmcid">PMC4568263</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>6240</fpage><pub-id pub-id-type="doi">10.1038/ncomms7240</pub-id><pub-id pub-id-type="pmid">25670642</pub-id><pub-id pub-id-type="pmcid">PMC4339892</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>LS</given-names></name><name name-style="western"><surname>Rickinson</surname><given-names>AB</given-names></name></person-group><article-title>Epstein-Barr virus: 40 years on</article-title><source>Nat. Rev. Cancer</source><year>2004</year><volume>4</volume><fpage>757</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1038/nrc1452</pub-id><pub-id pub-id-type="pmid">15510157</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanda</surname><given-names>T</given-names></name></person-group><article-title>EBV-encoded latent genes</article-title><source>Adv. Exp. Med. Biol.</source><year>2018</year><volume>1045</volume><fpage>377</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1007/978-981-10-7230-7_17</pub-id><pub-id pub-id-type="pmid">29896676</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murata</surname><given-names>T</given-names></name></person-group><article-title>Encyclopedia of EBV-encoded lytic genes: an update</article-title><source>Adv. Exp. Med. Biol.</source><year>2018</year><volume>1045</volume><fpage>395</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1007/978-981-10-7230-7_18</pub-id><pub-id pub-id-type="pmid">29896677</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luzuriaga</surname><given-names>K</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>JL</given-names></name></person-group><article-title>Infectious mononucleosis</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>362</volume><fpage>1993</fpage><lpage>2000</lpage><pub-id pub-id-type="doi">10.1056/NEJMcp1001116</pub-id><pub-id pub-id-type="pmid">20505178</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hjalgrim</surname><given-names>H</given-names></name><etal/></person-group><article-title>Characteristics of Hodgkin&#8217;s lymphoma after infectious mononucleosis</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>349</volume><fpage>1324</fpage><lpage>1332</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa023141</pub-id><pub-id pub-id-type="pmid">14523140</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheik-Ali</surname><given-names>S</given-names></name></person-group><article-title>Infectious mononucleosis and multiple sclerosis - Updated review on associated risk</article-title><source>Mult. Scler. Relat. Disord.</source><year>2017</year><volume>14</volume><fpage>56</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.msard.2017.02.019</pub-id><pub-id pub-id-type="pmid">28619433</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffey</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene</article-title><source>Nat. Genet.</source><year>1998</year><volume>20</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1038/2424</pub-id><pub-id pub-id-type="pmid">9771704</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seemayer</surname><given-names>TA</given-names></name><etal/></person-group><article-title>X-linked lymphoproliferative disease: twenty-five years after the discovery</article-title><source>Pediatr. Res.</source><year>1995</year><volume>38</volume><fpage>471</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1203/00006450-199510000-00001</pub-id><pub-id pub-id-type="pmid">8559596</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenspan</surname><given-names>JS</given-names></name><name name-style="western"><surname>Greenspan</surname><given-names>D</given-names></name><name name-style="western"><surname>Webster-Cyriaque</surname><given-names>J</given-names></name></person-group><article-title>Hairy leukoplakia; lessons learned: 30-plus years</article-title><source>Oral. Dis.</source><year>2016</year><volume>22</volume><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1111/odi.12393</pub-id><pub-id pub-id-type="pmid">27109280</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>H</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>JI</given-names></name></person-group><article-title>Chronic active Epstein-Barr virus disease</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1867</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01867</pub-id><pub-id pub-id-type="pmid">29375552</pub-id><pub-id pub-id-type="pmcid">PMC5770746</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paolucci</surname><given-names>S</given-names></name><etal/></person-group><article-title>EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count</article-title><source>Int. J. Infect. Dis.</source><year>2021</year><volume>104</volume><fpage>315</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.12.051</pub-id><pub-id pub-id-type="pmid">33359064</pub-id><pub-id pub-id-type="pmcid">PMC7833117</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name></person-group><article-title>Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>10902</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-90351-y</pub-id><pub-id pub-id-type="pmid">34035353</pub-id><pub-id pub-id-type="pmcid">PMC8149409</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nadeem</surname><given-names>A</given-names></name><name name-style="western"><surname>Suresh</surname><given-names>K</given-names></name><name name-style="western"><surname>Awais</surname><given-names>H</given-names></name><name name-style="western"><surname>Waseem</surname><given-names>S</given-names></name></person-group><article-title>Epstein-Barr virus coinfection in COVID-19</article-title><source>J. Investig. Med High. Impact Case Rep.</source><year>2021</year><volume>9</volume><fpage>23247096211040626</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/23247096211040626</pub-id><pub-id pub-id-type="pmcid">PMC8392798</pub-id><pub-id pub-id-type="pmid">34428954</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Gold, J. E., Okyay, R. A., Licht, W. E. &amp; Hurley, D. J. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. <italic toggle="yes">Pathogens</italic>10.3390/pathogens10060763 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathogens10060763</pub-id><pub-id pub-id-type="pmcid">PMC8233978</pub-id><pub-id pub-id-type="pmid">34204243</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niller</surname><given-names>HH</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>H</given-names></name><name name-style="western"><surname>Minarovits</surname><given-names>J</given-names></name></person-group><article-title>Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases</article-title><source>Autoimmunity</source><year>2008</year><volume>41</volume><fpage>298</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1080/08916930802024772</pub-id><pub-id pub-id-type="pmid">18432410</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Houen</surname><given-names>G</given-names></name><name name-style="western"><surname>Trier</surname><given-names>NH</given-names></name></person-group><article-title>Epstein-Barr virus and systemic autoimmune diseases</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>587380</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.587380</pub-id><pub-id pub-id-type="pmid">33488588</pub-id><pub-id pub-id-type="pmcid">PMC7817975</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bjornevik</surname><given-names>K</given-names></name><etal/></person-group><article-title>Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>296</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1126/science.abj8222</pub-id><pub-id pub-id-type="pmid">35025605</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lanz</surname><given-names>TV</given-names></name><etal/></person-group><article-title>Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM</article-title><source>Nature</source><year>2022</year><volume>603</volume><fpage>321</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04432-7</pub-id><pub-id pub-id-type="pmid">35073561</pub-id><pub-id pub-id-type="pmcid">PMC9382663</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>G</given-names></name><name name-style="western"><surname>Fitzmaurice</surname><given-names>C</given-names></name><name name-style="western"><surname>Naghavi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>LA</given-names></name></person-group><article-title>Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990-2017</article-title><source>BMJ Open</source><year>2020</year><volume>10</volume><fpage>e037505</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2020-037505</pub-id><pub-id pub-id-type="pmcid">PMC7462312</pub-id><pub-id pub-id-type="pmid">32868361</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Montes-Mojarro, I. A., Fend, F. &amp; Quintanilla-Martinez, L. EBV and the Pathogenesis of NK/T Cell Lymphoma. <italic toggle="yes">Cancers</italic>10.3390/cancers13061414 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13061414</pub-id><pub-id pub-id-type="pmcid">PMC8003370</pub-id><pub-id pub-id-type="pmid">33808787</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Gan</surname><given-names>R</given-names></name></person-group><article-title>Signaling pathways of EBV-induced oncogenesis</article-title><source>Cancer Cell Int.</source><year>2021</year><volume>21</volume><fpage>93</fpage><pub-id pub-id-type="doi">10.1186/s12935-021-01793-3</pub-id><pub-id pub-id-type="pmid">33549103</pub-id><pub-id pub-id-type="pmcid">PMC7868022</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>LS</given-names></name><name name-style="western"><surname>Murray</surname><given-names>PG</given-names></name></person-group><article-title>Epstein-Barr virus and oncogenesis: from latent genes to tumours</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>5108</fpage><lpage>5121</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206556</pub-id><pub-id pub-id-type="pmid">12910248</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujieda</surname><given-names>M</given-names></name><name name-style="western"><surname>Hattori</surname><given-names>M</given-names></name></person-group><article-title>Cancer-infection interface in children after transplantation: posttransplant lymphoproliferative disorder and Epstein-Barr virus infection</article-title><source>Curr. Opin. Organ Transpl.</source><year>2013</year><volume>18</volume><fpage>549</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1097/MOT.0b013e3283651b0d</pub-id><pub-id pub-id-type="pmid">23995375</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>M</given-names></name><name name-style="western"><surname>Michaels</surname><given-names>MG</given-names></name></person-group><article-title>Epstein-Barr virus infection and posttransplant lymphoproliferative disorder</article-title><source>Am. J. Transpl.</source><year>2013</year><volume>13</volume><fpage>41</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1111/ajt.12004</pub-id><pub-id pub-id-type="pmid">23347213</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>JI</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>AS</given-names></name><name name-style="western"><surname>Varmus</surname><given-names>H</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>GJ</given-names></name></person-group><article-title>Epstein-Barr virus: an important vaccine target for cancer prevention</article-title><source>Sci. Transl. Med.</source><year>2011</year><volume>3</volume><fpage>107fs107</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3002878</pub-id><pub-id pub-id-type="pmcid">PMC3501269</pub-id><pub-id pub-id-type="pmid">22049067</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>YP</given-names></name><etal/></person-group><article-title>Nasopharyngeal carcinoma</article-title><source>Lancet</source><year>2019</year><volume>394</volume><fpage>64</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)30956-0</pub-id><pub-id pub-id-type="pmid">31178151</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naseem</surname><given-names>M</given-names></name><etal/></person-group><article-title>Outlooks on Epstein-Barr virus associated gastric cancer</article-title><source>Cancer Treat. Rev.</source><year>2018</year><volume>66</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2018.03.006</pub-id><pub-id pub-id-type="pmid">29631196</pub-id><pub-id pub-id-type="pmcid">PMC5964025</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parkin</surname><given-names>DM</given-names></name></person-group><article-title>The global health burden of infection-associated cancers in the year 2002</article-title><source>Int J. Cancer</source><year>2006</year><volume>118</volume><fpage>3030</fpage><lpage>3044</lpage><pub-id pub-id-type="doi">10.1002/ijc.21731</pub-id><pub-id pub-id-type="pmid">16404738</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>G</given-names></name><name name-style="western"><surname>Hashim</surname><given-names>MJ</given-names></name></person-group><article-title>Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010</article-title><source>Infect. Agent Cancer</source><year>2014</year><volume>9</volume><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/1750-9378-9-38</pub-id><pub-id pub-id-type="pmid">25473414</pub-id><pub-id pub-id-type="pmcid">PMC4253616</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2000</year><volume>48</volume><fpage>1323</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1016/S0360-3016(00)00779-3</pub-id><pub-id pub-id-type="pmid">11121629</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chua</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials</article-title><source>J. Clin. Oncol.</source><year>2005</year><volume>23</volume><fpage>1118</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.12.081</pub-id><pub-id pub-id-type="pmid">15657403</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Short</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma</article-title><source>Am. J. Hematol.</source><year>2017</year><volume>92</volume><fpage>E114</fpage><lpage>E117</lpage><pub-id pub-id-type="doi">10.1002/ajh.24720</pub-id><pub-id pub-id-type="pmid">28295472</pub-id><pub-id pub-id-type="pmcid">PMC5828013</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>C</given-names></name><etal/></person-group><article-title>Immunization of common marmosets with Epstein-Barr virus (EBV) envelope glycoprotein gp340: effect on viral shedding following EBV challenge</article-title><source>J. Med. Virol.</source><year>1998</year><volume>55</volume><fpage>255</fpage><lpage>261</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1096-9071(199808)55:4&amp;#x0003c;255::AID-JMV1&amp;#x0003e;3.0.CO;2-#</pub-id><pub-id pub-id-type="pmid">9661832</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><etal/></person-group><article-title>A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>3039</fpage><lpage>3045</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.04.071</pub-id><pub-id pub-id-type="pmid">23665339</pub-id><pub-id pub-id-type="pmcid">PMC3700395</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emini</surname><given-names>EA</given-names></name><name name-style="western"><surname>Schleif</surname><given-names>WA</given-names></name><name name-style="western"><surname>Silberklang</surname><given-names>M</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>D</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>RW</given-names></name></person-group><article-title>Vero cell-expressed Epstein-Barr virus (EBV) gp350/220 protects marmosets from EBV challenge</article-title><source>J. Med. Virol.</source><year>1989</year><volume>27</volume><fpage>120</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1002/jmv.1890270210</pub-id><pub-id pub-id-type="pmid">2537882</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epstein</surname><given-names>MA</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><name name-style="western"><surname>Randle</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Kirkwood</surname><given-names>JK</given-names></name></person-group><article-title>Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine</article-title><source>Nature</source><year>1985</year><volume>318</volume><fpage>287</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/318287a0</pub-id><pub-id pub-id-type="pmid">2999604</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epstein</surname><given-names>MA</given-names></name><name name-style="western"><surname>Randle</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><name name-style="western"><surname>Kirkwood</surname><given-names>JK</given-names></name></person-group><article-title>Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals</article-title><source>Clin. Exp. Immunol.</source><year>1986</year><volume>63</volume><fpage>485</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">3011324</pub-id><pub-id pub-id-type="pmcid">PMC1577551</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><etal/></person-group><article-title>Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum</article-title><source>Vaccine</source><year>1994</year><volume>12</volume><fpage>1180</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(94)90240-2</pub-id><pub-id pub-id-type="pmid">7839721</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><etal/></person-group><article-title>Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector</article-title><source>J. Gen. Virol.</source><year>1992</year><volume>73</volume><fpage>449</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-73-2-449</pub-id><pub-id pub-id-type="pmid">1311367</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heeke</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>2562</fpage><lpage>2569</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.04.012</pub-id><pub-id pub-id-type="pmid">27085175</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackman</surname><given-names>WT</given-names></name><name name-style="western"><surname>Mann</surname><given-names>KA</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Spaete</surname><given-names>RR</given-names></name></person-group><article-title>Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine</article-title><source>Vaccine</source><year>1999</year><volume>17</volume><fpage>660</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(98)00248-5</pub-id><pub-id pub-id-type="pmid">10067671</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>S</given-names></name><etal/></person-group><article-title>DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen</article-title><source>Mol. Cells</source><year>2001</year><volume>12</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">11561729</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanekiyo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>1090</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.07.043</pub-id><pub-id pub-id-type="pmid">26279189</pub-id><pub-id pub-id-type="pmcid">PMC4757492</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>YF</given-names></name><etal/></person-group><article-title>Immunization with a self-assembled nanoparticle vaccine elicits potent neutralizing antibody responses against EBV infection</article-title><source>Nano Lett.</source><year>2021</year><volume>21</volume><fpage>2476</fpage><lpage>2486</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.0c04687</pub-id><pub-id pub-id-type="pmid">33683126</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanna</surname><given-names>R</given-names></name><name name-style="western"><surname>Sherritt</surname><given-names>M</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>SR</given-names></name></person-group><article-title>EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design</article-title><source>J. Immunol.</source><year>1999</year><volume>162</volume><fpage>3063</fpage><lpage>3069</lpage><pub-id pub-id-type="pmid">10072559</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackett</surname><given-names>M</given-names></name><name name-style="western"><surname>Arrand</surname><given-names>JR</given-names></name></person-group><article-title>Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340</article-title><source>EMBO J.</source><year>1985</year><volume>4</volume><fpage>3229</fpage><lpage>3234</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1985.tb04070.x</pub-id><pub-id pub-id-type="pmid">3004944</pub-id><pub-id pub-id-type="pmcid">PMC554647</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackett</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immunisation of common marmosets with vaccinia virus expressing Epstein-Barr virus (EBV) gp340 and challenge with EBV</article-title><source>J. Med. Virol.</source><year>1996</year><volume>50</volume><fpage>263</fpage><lpage>271</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1096-9071(199611)50:3&amp;#x0003c;263::AID-JMV9&amp;#x0003e;3.0.CO;2-7</pub-id><pub-id pub-id-type="pmid">8923292</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use</article-title><source>J. Med. Virol.</source><year>1989</year><volume>29</volume><fpage>74</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1002/jmv.1890290114</pub-id><pub-id pub-id-type="pmid">2555448</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>MA</given-names></name><name name-style="western"><surname>North</surname><given-names>JR</given-names></name></person-group><article-title>Comparative immunogenicity studies on Epstein-Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton-top tamarins</article-title><source>J. Med. Virol.</source><year>1984</year><volume>13</volume><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1002/jmv.1890130310</pub-id><pub-id pub-id-type="pmid">6327902</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><name name-style="western"><surname>Lovgren</surname><given-names>K</given-names></name><name name-style="western"><surname>Scullion</surname><given-names>FT</given-names></name><name name-style="western"><surname>Morein</surname><given-names>B</given-names></name></person-group><article-title>Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes</article-title><source>J. Gen. Virol.</source><year>1988</year><volume>69</volume><fpage>2093</fpage><lpage>2096</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-69-8-2093</pub-id><pub-id pub-id-type="pmid">2841417</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas</article-title><source>J. Med. Virol.</source><year>1988</year><volume>25</volume><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1002/jmv.1890250209</pub-id><pub-id pub-id-type="pmid">2839612</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>North</surname><given-names>JR</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>JL</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>MA</given-names></name></person-group><article-title>Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1982</year><volume>79</volume><fpage>7504</fpage><lpage>7508</lpage><pub-id pub-id-type="doi">10.1073/pnas.79.23.7504</pub-id><pub-id pub-id-type="pmid">6296836</pub-id><pub-id pub-id-type="pmcid">PMC347368</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogembo</surname><given-names>JG</given-names></name><etal/></person-group><article-title>A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice</article-title><source>J. Transl. Med.</source><year>2015</year><volume>13</volume><fpage>50</fpage><pub-id pub-id-type="doi">10.1186/s12967-015-0415-2</pub-id><pub-id pub-id-type="pmid">25885535</pub-id><pub-id pub-id-type="pmcid">PMC4328182</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qualtiere</surname><given-names>LF</given-names></name><name name-style="western"><surname>Chase</surname><given-names>R</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>GR</given-names></name></person-group><article-title>Purification and biologic characterization of a major Epstein Barr virus-induced membrane glycoprotein</article-title><source>J. Immunol.</source><year>1982</year><volume>129</volume><fpage>814</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">7086144</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ragot</surname><given-names>T</given-names></name><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>PE</given-names></name><name name-style="western"><surname>Perricaudet</surname><given-names>M</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name></person-group><article-title>Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin</article-title><source>J. Gen. Virol.</source><year>1993</year><volume>74</volume><fpage>501</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-74-3-501</pub-id><pub-id pub-id-type="pmid">8383183</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><fpage>5704</fpage><lpage>5718</lpage><pub-id pub-id-type="doi">10.7150/thno.42494</pub-id><pub-id pub-id-type="pmid">32483413</pub-id><pub-id pub-id-type="pmcid">PMC7255000</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>B</given-names></name><etal/></person-group><article-title>Immunization with Fc-based recombinant Epstein-Barr virus gp350 elicits potent neutralizing humoral immune response in a BALB/c mice model</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>932</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00932</pub-id><pub-id pub-id-type="pmid">29765376</pub-id><pub-id pub-id-type="pmcid">PMC5938345</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogel</surname><given-names>AB</given-names></name><etal/></person-group><article-title>BNT162b vaccines protect rhesus macaques from SARS-CoV-2</article-title><source>Nature</source><year>2021</year><volume>592</volume><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03275-y</pub-id><pub-id pub-id-type="pmid">33524990</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corbett</surname><given-names>KS</given-names></name><etal/></person-group><article-title>SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>567</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2622-0</pub-id><pub-id pub-id-type="pmid">32756549</pub-id><pub-id pub-id-type="pmcid">PMC7581537</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><mixed-citation publication-type="other">Qian, C. et al. Recent progress on the versatility of virus-like particles. <italic toggle="yes">Vaccines</italic>10.3390/vaccines8010139 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8010139</pub-id><pub-id pub-id-type="pmcid">PMC7157238</pub-id><pub-id pub-id-type="pmid">32244935</pub-id></mixed-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorley-Lawson</surname><given-names>DA</given-names></name></person-group><article-title>A virus-free immunogen effective against Epstein-Barr virus</article-title><source>Nature</source><year>1979</year><volume>281</volume><fpage>486</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1038/281486a0</pub-id><pub-id pub-id-type="pmid">226890</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><etal/></person-group><article-title>Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>4050</fpage><lpage>4055</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.06.021</pub-id><pub-id pub-id-type="pmid">27291087</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells</article-title><source>Immunity</source><year>2019</year><volume>50</volume><fpage>1305</fpage><lpage>1316 e1306</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.010</pub-id><pub-id pub-id-type="pmid">30979688</pub-id><pub-id pub-id-type="pmcid">PMC6660903</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malhi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge</article-title><source>Cell Rep. Med.</source><year>2022</year><volume>3</volume><fpage>100658</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2022.100658</pub-id><pub-id pub-id-type="pmid">35705092</pub-id><pub-id pub-id-type="pmcid">PMC9245003</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><mixed-citation publication-type="other">Escalante, G. M. et al. A Pentavalent Epstein-Barr virus-like particle vaccine elicits high titers of neutralizing antibodies against Epstein-Barr virus infection in immunized rabbits. <italic toggle="yes">Vaccines</italic>10.3390/vaccines8020169 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8020169</pub-id><pub-id pub-id-type="pmcid">PMC7349562</pub-id><pub-id pub-id-type="pmid">32268575</pub-id></mixed-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice</article-title><source>Sci. Transl. Med.</source><year>2022</year><volume>14</volume><fpage>eabf3685</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abf3685</pub-id><pub-id pub-id-type="pmid">35507671</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakravorty</surname><given-names>A</given-names></name><name name-style="western"><surname>Sugden</surname><given-names>B</given-names></name></person-group><article-title>The AT-hook DNA binding ability of the Epstein Barr virus EBNA1 protein is necessary for the maintenance of viral genomes in latently infected cells</article-title><source>Virology</source><year>2015</year><volume>484</volume><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2015.05.018</pub-id><pub-id pub-id-type="pmid">26122471</pub-id><pub-id pub-id-type="pmcid">PMC4567472</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blake</surname><given-names>N</given-names></name><etal/></person-group><article-title>Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing</article-title><source>Immunity</source><year>1997</year><volume>7</volume><fpage>791</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80397-0</pub-id><pub-id pub-id-type="pmid">9430224</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>HM</given-names></name><etal/></person-group><article-title>CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>4896</fpage><lpage>4907</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.8.4896-4907.2005</pub-id><pub-id pub-id-type="pmid">15795275</pub-id><pub-id pub-id-type="pmcid">PMC1069546</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munz</surname><given-names>C</given-names></name><etal/></person-group><article-title>Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1</article-title><source>J. Exp. Med.</source><year>2000</year><volume>191</volume><fpage>1649</fpage><lpage>1660</lpage><pub-id pub-id-type="doi">10.1084/jem.191.10.1649</pub-id><pub-id pub-id-type="pmid">10811859</pub-id><pub-id pub-id-type="pmcid">PMC2193162</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikiforow</surname><given-names>S</given-names></name><name name-style="western"><surname>Bottomly</surname><given-names>K</given-names></name><name name-style="western"><surname>Miller</surname><given-names>G</given-names></name><name name-style="western"><surname>Munz</surname><given-names>C</given-names></name></person-group><article-title>Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>12088</fpage><lpage>12104</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.22.12088-12104.2003</pub-id><pub-id pub-id-type="pmid">14581546</pub-id><pub-id pub-id-type="pmcid">PMC254269</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paludan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt&#8217;s lymphoma cells</article-title><source>J. Immunol.</source><year>2002</year><volume>169</volume><fpage>1593</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.3.1593</pub-id><pub-id pub-id-type="pmid">12133989</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>1231</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-03-148072</pub-id><pub-id pub-id-type="pmid">18519810</pub-id><pub-id pub-id-type="pmcid">PMC2515117</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruhl</surname><given-names>J</given-names></name><etal/></person-group><article-title>Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas</article-title><source>J. Clin. Invest</source><year>2019</year><volume>129</volume><fpage>2071</fpage><lpage>2087</lpage><pub-id pub-id-type="doi">10.1172/JCI125364</pub-id><pub-id pub-id-type="pmid">31042161</pub-id><pub-id pub-id-type="pmcid">PMC6486346</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Early T cell recognition of B cells following Epstein-Barr virus infection: identifying potential targets for prophylactic vaccination</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><fpage>e1005549</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1005549</pub-id><pub-id pub-id-type="pmid">27096949</pub-id><pub-id pub-id-type="pmcid">PMC4838210</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartlage</surname><given-names>AS</given-names></name><etal/></person-group><article-title>The Epstein-Barr virus lytic protein BZLF1 as a candidate target antigen for vaccine development</article-title><source>Cancer Immunol. Res.</source><year>2015</year><volume>3</volume><fpage>787</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0242</pub-id><pub-id pub-id-type="pmid">25735952</pub-id><pub-id pub-id-type="pmcid">PMC4491000</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lockey</surname><given-names>TD</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>X</given-names></name><name name-style="western"><surname>Surman</surname><given-names>S</given-names></name><name name-style="western"><surname>Sample</surname><given-names>CE</given-names></name><name name-style="western"><surname>Hurwitz</surname><given-names>JL</given-names></name></person-group><article-title>Epstein-Barr virus vaccine development: a lytic and latent protein cocktail</article-title><source>Front. Biosci.</source><year>2008</year><volume>13</volume><fpage>5916</fpage><lpage>5927</lpage><pub-id pub-id-type="doi">10.2741/3126</pub-id><pub-id pub-id-type="pmid">18508632</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>EM</given-names></name><name name-style="western"><surname>Foley</surname><given-names>J</given-names></name><name name-style="western"><surname>Tison</surname><given-names>T</given-names></name><name name-style="western"><surname>Silva</surname><given-names>R</given-names></name><name name-style="western"><surname>Ogembo</surname><given-names>JG</given-names></name></person-group><article-title>Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>19255</fpage><lpage>19273</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.13770</pub-id><pub-id pub-id-type="pmid">27926486</pub-id><pub-id pub-id-type="pmcid">PMC5386682</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hettich</surname><given-names>E</given-names></name><etal/></person-group><article-title>Genetic design of an optimized packaging cell line for gene vectors transducing human B cells</article-title><source>Gene Ther.</source><year>2006</year><volume>13</volume><fpage>844</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3302714</pub-id><pub-id pub-id-type="pmid">16421600</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiss</surname><given-names>R</given-names></name><etal/></person-group><article-title>A virus-like particle-based Epstein-Barr virus vaccine</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>13105</fpage><lpage>13113</lpage><pub-id pub-id-type="doi">10.1128/JVI.05598-11</pub-id><pub-id pub-id-type="pmid">21994444</pub-id><pub-id pub-id-type="pmcid">PMC3233152</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavlova</surname><given-names>S</given-names></name><etal/></person-group><article-title>An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>2011</fpage><lpage>2022</lpage><pub-id pub-id-type="doi">10.1128/JVI.02533-12</pub-id><pub-id pub-id-type="pmid">23236073</pub-id><pub-id pub-id-type="pmcid">PMC3571473</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Zyl</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice</article-title><source>PLoS Pathog.</source><year>2018</year><volume>14</volume><fpage>e1007464</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1007464</pub-id><pub-id pub-id-type="pmid">30521644</pub-id><pub-id pub-id-type="pmcid">PMC6298685</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shumilov</surname><given-names>A</given-names></name><etal/></person-group><article-title>Epstein-Barr virus particles induce centrosome amplification and chromosomal instability</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>14257</fpage><pub-id pub-id-type="doi">10.1038/ncomms14257</pub-id><pub-id pub-id-type="pmid">28186092</pub-id><pub-id pub-id-type="pmcid">PMC5309802</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yiu</surname><given-names>SPT</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R</given-names></name><name name-style="western"><surname>Zerbe</surname><given-names>C</given-names></name><name name-style="western"><surname>Weekes</surname><given-names>MP</given-names></name><name name-style="western"><surname>Gewurz</surname><given-names>BE</given-names></name></person-group><article-title>Epstein-Barr virus BNRF1 destabilizes SMC5/6 cohesin complexes to evade its restriction of replication compartments</article-title><source>Cell Rep.</source><year>2022</year><volume>38</volume><fpage>110411</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2022.110411</pub-id><pub-id pub-id-type="pmid">35263599</pub-id><pub-id pub-id-type="pmcid">PMC8981113</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munz</surname><given-names>C</given-names></name></person-group><article-title>Humanized mouse models for Epstein Barr virus infection</article-title><source>Curr. Opin. Virol.</source><year>2017</year><volume>25</volume><fpage>113</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2017.07.026</pub-id><pub-id pub-id-type="pmid">28837889</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><mixed-citation publication-type="other">Chen, H. et al. Dose-dependent outcome of EBV infection of humanized mice based on green Raji unit (GRU) doses. <italic toggle="yes">Viruses</italic>10.3390/v13112184 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13112184</pub-id><pub-id pub-id-type="pmcid">PMC8624110</pub-id><pub-id pub-id-type="pmid">34834989</pub-id></mixed-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>B</given-names></name><name name-style="western"><surname>Leung</surname><given-names>CS</given-names></name><name name-style="western"><surname>Munz</surname><given-names>C</given-names></name></person-group><article-title>Animal models of Epstein Barr virus infection</article-title><source>J. Immunol. Methods</source><year>2014</year><volume>410</volume><fpage>80</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2014.04.009</pub-id><pub-id pub-id-type="pmid">24815603</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujiwara</surname><given-names>S</given-names></name><name name-style="western"><surname>Imadome</surname><given-names>K</given-names></name><name name-style="western"><surname>Takei</surname><given-names>M</given-names></name></person-group><article-title>Modeling EBV infection and pathogenesis in new-generation humanized mice</article-title><source>Exp. Mol. Med.</source><year>2015</year><volume>47</volume><fpage>e135</fpage><pub-id pub-id-type="doi">10.1038/emm.2014.88</pub-id><pub-id pub-id-type="pmid">25613732</pub-id><pub-id pub-id-type="pmcid">PMC4314584</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><mixed-citation publication-type="other">Munz, C. Immune control and vaccination against the Epstein-Barr virus in humanized mice. <italic toggle="yes">Vaccines</italic>10.3390/vaccines7040217 (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines7040217</pub-id><pub-id pub-id-type="pmcid">PMC6963577</pub-id><pub-id pub-id-type="pmid">31861045</pub-id></mixed-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chijioke</surname><given-names>O</given-names></name><etal/></person-group><article-title>Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection</article-title><source>Cell Rep.</source><year>2013</year><volume>5</volume><fpage>1489</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.11.041</pub-id><pub-id pub-id-type="pmid">24360958</pub-id><pub-id pub-id-type="pmcid">PMC3895765</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munz</surname><given-names>C</given-names></name></person-group><article-title>EBV infection of mice with reconstituted human immune system components</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2015</year><volume>391</volume><fpage>407</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">26428383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-319-22834-1_14</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yajima</surname><given-names>M</given-names></name><etal/></person-group><article-title>A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses</article-title><source>J. Infect. Dis.</source><year>2008</year><volume>198</volume><fpage>673</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1086/590502</pub-id><pub-id pub-id-type="pmid">18627269</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takashima</surname><given-names>K</given-names></name><etal/></person-group><article-title>A new animal model for primary and persistent Epstein-Barr virus infection: human EBV-infected rabbit characteristics determined using sequential imaging and pathological analysis</article-title><source>J. Med. Virol.</source><year>2008</year><volume>80</volume><fpage>455</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1002/jmv.21102</pub-id><pub-id pub-id-type="pmid">18205213</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okuno</surname><given-names>K</given-names></name><etal/></person-group><article-title>Epstein-Barr virus can infect rabbits by the intranasal or peroral route: an animal model for natural primary EBV infection in humans</article-title><source>J. Med. Virol.</source><year>2010</year><volume>82</volume><fpage>977</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1002/jmv.21597</pub-id><pub-id pub-id-type="pmid">20419811</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajcani</surname><given-names>J</given-names></name><etal/></person-group><article-title>Epstein-Barr virus (HHV-4) inoculation to rabbits by intranasal and oral routes results in subacute and/or persistent infection dissimilar to human disease</article-title><source>Intervirology</source><year>2014</year><volume>57</volume><fpage>254</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1159/000360223</pub-id><pub-id pub-id-type="pmid">24993954</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>G</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>W</given-names></name><name name-style="western"><surname>Philip</surname><given-names>PS</given-names></name><name name-style="western"><surname>Ali</surname><given-names>MH</given-names></name><name name-style="western"><surname>Adem</surname><given-names>A</given-names></name></person-group><article-title>Healthy rabbits are susceptible to Epstein-Barr virus infection and infected cells proliferate in immunosuppressed animals</article-title><source>Virol. J.</source><year>2015</year><volume>12</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s12985-015-0260-1</pub-id><pub-id pub-id-type="pmid">25851649</pub-id><pub-id pub-id-type="pmcid">PMC4340116</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moghaddam</surname><given-names>A</given-names></name><etal/></person-group><article-title>An animal model for acute and persistent Epstein-Barr virus infection</article-title><source>Science</source><year>1997</year><volume>276</volume><fpage>2030</fpage><lpage>2033</lpage><pub-id pub-id-type="doi">10.1126/science.276.5321.2030</pub-id><pub-id pub-id-type="pmid">9197263</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name></person-group><article-title>Nonhuman primate models for Epstein-Barr virus infection</article-title><source>Curr. Opin. Virol.</source><year>2013</year><volume>3</volume><fpage>233</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2013.03.003</pub-id><pub-id pub-id-type="pmid">23562212</pub-id><pub-id pub-id-type="pmcid">PMC3713193</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivailler</surname><given-names>P</given-names></name><etal/></person-group><article-title>Experimental rhesus lymphocryptovirus infection in immunosuppressed macaques: an animal model for Epstein-Barr virus pathogenesis in the immunosuppressed host</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>1482</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-01-0342</pub-id><pub-id pub-id-type="pmid">15150077</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujiwara</surname><given-names>S</given-names></name></person-group><article-title>Animal models of human gammaherpesvirus infections</article-title><source>Adv. Exp. Med. Biol.</source><year>2018</year><volume>1045</volume><fpage>413</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1007/978-981-10-7230-7_19</pub-id><pub-id pub-id-type="pmid">29896678</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sashihara</surname><given-names>J</given-names></name><etal/></person-group><article-title>Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge</article-title><source>PLoS Pathog.</source><year>2011</year><volume>7</volume><fpage>e1002308</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1002308</pub-id><pub-id pub-id-type="pmid">22028652</pub-id><pub-id pub-id-type="pmcid">PMC3197588</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhe</surname><given-names>J</given-names></name><etal/></person-group><article-title>Neutralizing antibodies against Epstein-Barr virus infection of B cells can protect from oral viral challenge in the rhesus macaque animal model</article-title><source>Cell Rep. Med.</source><year>2021</year><volume>2</volume><fpage>100352</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100352</pub-id><pub-id pub-id-type="pmid">34337567</pub-id><pub-id pub-id-type="pmcid">PMC8324488</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werner</surname><given-names>J</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>H</given-names></name><name name-style="western"><surname>Apodaca</surname><given-names>J</given-names></name><name name-style="western"><surname>zur Hausen</surname><given-names>H</given-names></name></person-group><article-title>Lymphoproliferative disease in a cotton-top marmoset after inoculation with infectious mononucleosis-derived Epstein-Barr virus</article-title><source>Int. J. Cancer</source><year>1975</year><volume>15</volume><fpage>1000</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910150617</pub-id><pub-id pub-id-type="pmid">168158</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>G</given-names></name><etal/></person-group><article-title>Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum antibody responses, demonstration of viral DNA, and characterization of viruses</article-title><source>J. Exp. Med.</source><year>1977</year><volume>145</volume><fpage>948</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1084/jem.145.4.948</pub-id><pub-id pub-id-type="pmid">192829</pub-id><pub-id pub-id-type="pmcid">PMC2180630</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cleary</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones</article-title><source>Science</source><year>1985</year><volume>228</volume><fpage>722</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1126/science.2986287</pub-id><pub-id pub-id-type="pmid">2986287</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finerty</surname><given-names>S</given-names></name><name name-style="western"><surname>Scullion</surname><given-names>FT</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>AJ</given-names></name></person-group><article-title>Demonstration in vitro of cell mediated immunity to Epstein-Barr virus in cotton-top tamarins</article-title><source>Clin. Exp. Immunol.</source><year>1988</year><volume>73</volume><fpage>181</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">2846217</pub-id><pub-id pub-id-type="pmcid">PMC1541596</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falk</surname><given-names>L</given-names></name><etal/></person-group><article-title>Epstein-Barr virus: experimental infection of Callithrix jacchus marmosets</article-title><source>Int. J. Cancer</source><year>1976</year><volume>17</volume><fpage>785</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910170615</pub-id><pub-id pub-id-type="pmid">181333</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de-The</surname><given-names>G</given-names></name><etal/></person-group><article-title>Natural antibodies to EBV-VCA antigens in common marmosets (Callithrix jacchus) and response after EBV inoculation</article-title><source>Intervirology</source><year>1980</year><volume>14</volume><fpage>284</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1159/000149198</pub-id><pub-id pub-id-type="pmid">6265400</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desgranges</surname><given-names>C</given-names></name><etal/></person-group><article-title>In vitro transforming activity of EBV. I-Establishment and properties of two EBV strains (M81 and M72) produced by immortalized Callithrix jacchus lymphocytes</article-title><source>Biomedicine</source><year>1976</year><volume>25</volume><fpage>349</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">187263</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wedderburn</surname><given-names>N</given-names></name><etal/></person-group><article-title>Infectious mononucleosis-like response in common marmosets infected with Epstein-Barr virus</article-title><source>J. Infect. Dis.</source><year>1984</year><volume>150</volume><fpage>878</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1093/infdis/150.6.878</pub-id><pub-id pub-id-type="pmid">6094675</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emini</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Establishment and characterization of a chronic infectious mononucleosislike syndrome in common marmosets</article-title><source>J. Med. Virol.</source><year>1986</year><volume>18</volume><fpage>369</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1002/jmv.1890180410</pub-id><pub-id pub-id-type="pmid">3011982</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epstein</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>RD</given-names></name><name name-style="western"><surname>Rabin</surname><given-names>H</given-names></name></person-group><article-title>Pilot experiments with EB virus in owl monkeys (Aotus trivirgatus). I Reticuloproliferative disease in an inoculated animal</article-title><source>Int. J. Cancer</source><year>1973</year><volume>12</volume><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910120202</pub-id><pub-id pub-id-type="pmid">4365091</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epstein</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Pilot experiments with EB virus in owl monkeys (Aotus trivirgatus). II. EB virus in a cell line from an animal with reticuloproliferative disease</article-title><source>Int. J. Cancer</source><year>1973</year><volume>12</volume><fpage>319</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910120203</pub-id><pub-id pub-id-type="pmid">4134122</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>SY</given-names></name><etal/></person-group><article-title>First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen</article-title><source>Dev. Biol. Stand.</source><year>1995</year><volume>84</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">7796951</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moutschen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>4697</fpage><lpage>4705</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.04.008</pub-id><pub-id pub-id-type="pmid">17485150</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sokal</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults</article-title><source>J. Infect. Dis.</source><year>2007</year><volume>196</volume><fpage>1749</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1086/523813</pub-id><pub-id pub-id-type="pmid">18190254</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rees</surname><given-names>L</given-names></name><etal/></person-group><article-title>A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation</article-title><source>Transplantation</source><year>2009</year><volume>88</volume><fpage>1025</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1097/TP.0b013e3181b9d918</pub-id><pub-id pub-id-type="pmid">19855249</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elliott</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>1448</fpage><lpage>1457</lpage><pub-id pub-id-type="doi">10.1128/JVI.01409-07</pub-id><pub-id pub-id-type="pmid">18032491</pub-id><pub-id pub-id-type="pmcid">PMC2224445</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bharucha</surname><given-names>T</given-names></name><name name-style="western"><surname>Ming</surname><given-names>D</given-names></name><name name-style="western"><surname>Breuer</surname><given-names>J</given-names></name></person-group><article-title>A critical appraisal of &#8216;Shingrix&#8217;, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus</article-title><source>Hum. Vaccin. Immunother.</source><year>2017</year><volume>13</volume><fpage>1789</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1317410</pub-id><pub-id pub-id-type="pmid">28426274</pub-id><pub-id pub-id-type="pmcid">PMC5557227</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lanzavecchia</surname><given-names>A</given-names></name><name name-style="western"><surname>Fruhwirth</surname><given-names>A</given-names></name><name name-style="western"><surname>Perez</surname><given-names>L</given-names></name><name name-style="western"><surname>Corti</surname><given-names>D</given-names></name></person-group><article-title>Antibody-guided vaccine design: identification of protective epitopes</article-title><source>Curr. Opin. Immunol.</source><year>2016</year><volume>41</volume><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2016.06.001</pub-id><pub-id pub-id-type="pmid">27343848</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>375</volume><fpage>1019</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1603800</pub-id><pub-id pub-id-type="pmid">27626517</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>P</given-names></name></person-group><article-title>The T cell immune response against SARS-CoV-2</article-title><source>Nat. Immunol.</source><year>2022</year><volume>23</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01122-w</pub-id><pub-id pub-id-type="pmid">35105982</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ito</surname><given-names>A</given-names></name></person-group><article-title>Tailoring inorganic nanoadjuvants towards next-generation vaccines</article-title><source>Chem. Soc. Rev.</source><year>2018</year><volume>47</volume><fpage>4954</fpage><lpage>4980</lpage><pub-id pub-id-type="doi">10.1039/C8CS00028J</pub-id><pub-id pub-id-type="pmid">29911725</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marshall</surname><given-names>NB</given-names></name><name name-style="western"><surname>Swain</surname><given-names>SL</given-names></name></person-group><article-title>Cytotoxic CD4 T cells in antiviral immunity</article-title><source>J. Biomed. Biotechnol.</source><year>2011</year><volume>2011</volume><fpage>954602</fpage><pub-id pub-id-type="doi">10.1155/2011/954602</pub-id><pub-id pub-id-type="pmid">22174559</pub-id><pub-id pub-id-type="pmcid">PMC3228492</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosendahl Huber</surname><given-names>S</given-names></name><name name-style="western"><surname>van Beek</surname><given-names>J</given-names></name><name name-style="western"><surname>de Jonge</surname><given-names>J</given-names></name><name name-style="western"><surname>Luytjes</surname><given-names>W</given-names></name><name name-style="western"><surname>van Baarle</surname><given-names>D</given-names></name></person-group><article-title>T cell responses to viral infections - opportunities for Peptide vaccination</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>171</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00171</pub-id><pub-id pub-id-type="pmid">24795718</pub-id><pub-id pub-id-type="pmcid">PMC3997009</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Zyl</surname><given-names>DG</given-names></name><name name-style="western"><surname>Mautner</surname><given-names>J</given-names></name><name name-style="western"><surname>Delecluse</surname><given-names>HJ</given-names></name></person-group><article-title>Progress in EBV vaccines</article-title><source>Front. Oncol.</source><year>2019</year><volume>9</volume><fpage>104</fpage><pub-id pub-id-type="doi">10.3389/fonc.2019.00104</pub-id><pub-id pub-id-type="pmid">30859093</pub-id><pub-id pub-id-type="pmcid">PMC6398348</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>GS</given-names></name><name name-style="western"><surname>Long</surname><given-names>HM</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rickinson</surname><given-names>AB</given-names></name><name name-style="western"><surname>Hislop</surname><given-names>AD</given-names></name></person-group><article-title>The immunology of Epstein-Barr virus-induced disease</article-title><source>Annu. Rev. Immunol.</source><year>2015</year><volume>33</volume><fpage>787</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032414-112326</pub-id><pub-id pub-id-type="pmid">25706097</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutt-Fletcher</surname><given-names>LM</given-names></name></person-group><article-title>EBV glycoproteins: where are we now?</article-title><source>Future Virol.</source><year>2015</year><volume>10</volume><fpage>1155</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.2217/fvl.15.80</pub-id><pub-id pub-id-type="pmid">26843889</pub-id><pub-id pub-id-type="pmcid">PMC4734392</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name></person-group><article-title>Heterologous prime-boost vaccination</article-title><source>Curr. Opin. Immunol.</source><year>2009</year><volume>21</volume><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2009.05.016</pub-id><pub-id pub-id-type="pmid">19500964</pub-id><pub-id pub-id-type="pmcid">PMC3743086</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><mixed-citation publication-type="other">Sapkota, B. et al. Heterologous prime-boost strategies for COVID-19 vaccines. <italic toggle="yes">J. Travel Med.</italic>10.1093/jtm/taab191 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jtm/taab191</pub-id><pub-id pub-id-type="pmcid">PMC8754745</pub-id><pub-id pub-id-type="pmid">34918097</pub-id></mixed-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pal</surname><given-names>R</given-names></name><etal/></person-group><article-title>Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype</article-title><source>Virology</source><year>2006</year><volume>348</volume><fpage>341</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2005.12.029</pub-id><pub-id pub-id-type="pmid">16460776</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>1098</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.12.024</pub-id><pub-id pub-id-type="pmid">18243434</pub-id><pub-id pub-id-type="pmcid">PMC2288749</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bansal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>6458</fpage><lpage>6469</lpage><pub-id pub-id-type="doi">10.1128/JVI.00068-08</pub-id><pub-id pub-id-type="pmid">18448544</pub-id><pub-id pub-id-type="pmcid">PMC2447094</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amara</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine</article-title><source>Science</source><year>2001</year><volume>292</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1126/science.292.5514.69</pub-id><pub-id pub-id-type="pmid">11393868</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiver</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity</article-title><source>Nature</source><year>2002</year><volume>415</volume><fpage>331</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1038/415331a</pub-id><pub-id pub-id-type="pmid">11797011</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sin</surname><given-names>JI</given-names></name><name name-style="western"><surname>Bagarazzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Pachuk</surname><given-names>C</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>DB</given-names></name></person-group><article-title>DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model</article-title><source>DNA Cell Biol.</source><year>1999</year><volume>18</volume><fpage>771</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1089/104454999314917</pub-id><pub-id pub-id-type="pmid">10541436</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavelle</surname><given-names>EC</given-names></name><name name-style="western"><surname>Ward</surname><given-names>RW</given-names></name></person-group><article-title>Mucosal vaccines - fortifying the frontiers</article-title><source>Nat. Rev. Immunol.</source><year>2022</year><volume>22</volume><fpage>236</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00583-2</pub-id><pub-id pub-id-type="pmid">34312520</pub-id><pub-id pub-id-type="pmcid">PMC8312369</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>1654</fpage><lpage>1664</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00396-0</pub-id><pub-id pub-id-type="pmid">34324836</pub-id><pub-id pub-id-type="pmcid">PMC8313090</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachmann</surname><given-names>MF</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>GT</given-names></name></person-group><article-title>Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns</article-title><source>Nat. Rev. Immunol.</source><year>2010</year><volume>10</volume><fpage>787</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1038/nri2868</pub-id><pub-id pub-id-type="pmid">20948547</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><mixed-citation publication-type="other">Le, D. T. &amp; Muller, K. M. In vitro assembly of virus-like particles and their applications. <italic toggle="yes">Life</italic>10.3390/life11040334 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/life11040334</pub-id><pub-id pub-id-type="pmcid">PMC8069851</pub-id><pub-id pub-id-type="pmid">33920215</pub-id></mixed-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assis</surname><given-names>BRD</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>CD</given-names></name><name name-style="western"><surname>Santiago</surname><given-names>MG</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>LAM</given-names></name><name name-style="western"><surname>Goulart</surname><given-names>GAC</given-names></name></person-group><article-title>Nanotechnology in adjuvants and vaccine development: what should we know?</article-title><source>Nanomed.</source><year>2021</year><volume>16</volume><fpage>2565</fpage><lpage>2568</lpage><pub-id pub-id-type="doi">10.2217/nnm-2021-0360</pub-id><pub-id pub-id-type="pmid">34802258</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irvine</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>MC</given-names></name><name name-style="western"><surname>Rakhra</surname><given-names>K</given-names></name><name name-style="western"><surname>Tokatlian</surname><given-names>T</given-names></name></person-group><article-title>Synthetic nanoparticles for vaccines and immunotherapy</article-title><source>Chem. Rev.</source><year>2015</year><volume>115</volume><fpage>11109</fpage><lpage>11146</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.5b00109</pub-id><pub-id pub-id-type="pmid">26154342</pub-id><pub-id pub-id-type="pmcid">PMC4688911</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><mixed-citation publication-type="other">Gutjahr, A. et al. Biodegradable polymeric nanoparticles-based vaccine adjuvants for lymph nodes targeting. <italic toggle="yes">Vaccines</italic>10.3390/vaccines4040034 (2016).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines4040034</pub-id><pub-id pub-id-type="pmcid">PMC5192354</pub-id><pub-id pub-id-type="pmid">27754314</pub-id></mixed-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pati</surname><given-names>R</given-names></name><name name-style="western"><surname>Shevtsov</surname><given-names>M</given-names></name><name name-style="western"><surname>Sonawane</surname><given-names>A</given-names></name></person-group><article-title>Nanoparticle vaccines against infectious diseases</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2224</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02224</pub-id><pub-id pub-id-type="pmid">30337923</pub-id><pub-id pub-id-type="pmcid">PMC6180194</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zacharias</surname><given-names>ZR</given-names></name><etal/></person-group><article-title>Polyanhydride nanovaccine induces robust pulmonary B and T cell immunity and confers protection against homologous and heterologous influenza A virus infections</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1953</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01953</pub-id><pub-id pub-id-type="pmid">30233573</pub-id><pub-id pub-id-type="pmcid">PMC6127617</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiao</surname><given-names>D</given-names></name><etal/></person-group><article-title>Potency of a scalable nanoparticulate subunit vaccine</article-title><source>Nano Lett.</source><year>2018</year><volume>18</volume><fpage>3007</fpage><lpage>3016</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.8b00478</pub-id><pub-id pub-id-type="pmid">29694053</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>SG</given-names></name><name name-style="western"><surname>Orr</surname><given-names>MT</given-names></name><name name-style="western"><surname>Fox</surname><given-names>CB</given-names></name></person-group><article-title>Key roles of adjuvants in modern vaccines</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>1597</fpage><lpage>1608</lpage><pub-id pub-id-type="doi">10.1038/nm.3409</pub-id><pub-id pub-id-type="pmid">24309663</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B</given-names></name><name name-style="western"><surname>P</surname><given-names>SA</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name></person-group><article-title>Emerging concepts in the science of vaccine adjuvants</article-title><source>Nat. Rev. Drug Disco.</source><year>2021</year><volume>20</volume><fpage>454</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id><pub-id pub-id-type="pmid">33824489</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imanishi</surname><given-names>T</given-names></name><name name-style="western"><surname>Saito</surname><given-names>T</given-names></name></person-group><article-title>T cell co-stimulation and functional modulation by innate signals</article-title><source>Trends Immunol.</source><year>2020</year><volume>41</volume><fpage>200</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.it.2020.01.003</pub-id><pub-id pub-id-type="pmid">32035763</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruprecht</surname><given-names>CR</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><article-title>Toll-like receptor stimulation as a third signal required for activation of human naive B cells</article-title><source>Eur. J. Immunol.</source><year>2006</year><volume>36</volume><fpage>810</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1002/eji.200535744</pub-id><pub-id pub-id-type="pmid">16541472</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R</given-names></name></person-group><article-title>Immunological mechanisms of vaccination</article-title><source>Nat. Immunol.</source><year>2011</year><volume>12</volume><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/ni.2039</pub-id><pub-id pub-id-type="pmid">21739679</pub-id><pub-id pub-id-type="pmcid">PMC3253344</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alving</surname><given-names>CR</given-names></name><name name-style="western"><surname>Peachman</surname><given-names>KK</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M</given-names></name><name name-style="western"><surname>Reed</surname><given-names>SG</given-names></name></person-group><article-title>Adjuvants for human vaccines</article-title><source>Curr. Opin. Immunol.</source><year>2012</year><volume>24</volume><fpage>310</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2012.03.008</pub-id><pub-id pub-id-type="pmid">22521140</pub-id><pub-id pub-id-type="pmcid">PMC3383374</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLellan</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody</article-title><source>Science</source><year>2013</year><volume>340</volume><fpage>1113</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1126/science.1234914</pub-id><pub-id pub-id-type="pmid">23618766</pub-id><pub-id pub-id-type="pmcid">PMC4459498</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLellan</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>592</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1126/science.1243283</pub-id><pub-id pub-id-type="pmid">24179220</pub-id><pub-id pub-id-type="pmcid">PMC4461862</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2</article-title><source>Natl Sci. Rev.</source><year>2021</year><volume>8</volume><fpage>nwab053</fpage><pub-id pub-id-type="doi">10.1093/nsr/nwab053</pub-id><pub-id pub-id-type="pmid">34676098</pub-id><pub-id pub-id-type="pmcid">PMC8083607</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>CO</given-names></name><etal/></person-group><article-title>SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies</article-title><source>Nature</source><year>2020</year><volume>588</volume><fpage>682</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2852-1</pub-id><pub-id pub-id-type="pmid">33045718</pub-id><pub-id pub-id-type="pmcid">PMC8092461</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snijder</surname><given-names>J</given-names></name><etal/></person-group><article-title>An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on Epstein-Barr virus</article-title><source>Immunity</source><year>2018</year><volume>48</volume><fpage>799</fpage><lpage>811 e799</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.026</pub-id><pub-id pub-id-type="pmid">29669253</pub-id><pub-id pub-id-type="pmcid">PMC5909843</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sathiyamoorthy</surname><given-names>K</given-names></name><etal/></person-group><article-title>Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>E8703</fpage><lpage>E8710</lpage><pub-id pub-id-type="doi">10.1073/pnas.1704661114</pub-id><pub-id pub-id-type="pmid">28939750</pub-id><pub-id pub-id-type="pmcid">PMC5642686</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><mixed-citation publication-type="other">Hong, J. et al. Antibody generation and immunogenicity analysis of EBV gp42 N-terminal region. <italic toggle="yes">Viruses</italic>10.3390/v13122380 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13122380</pub-id><pub-id pub-id-type="pmcid">PMC8707153</pub-id><pub-id pub-id-type="pmid">34960650</pub-id></mixed-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2022</year><volume>119</volume><fpage>e2202371119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2202371119</pub-id><pub-id pub-id-type="pmid">35917353</pub-id><pub-id pub-id-type="pmcid">PMC9371650</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collie</surname><given-names>S</given-names></name><name name-style="western"><surname>Champion</surname><given-names>J</given-names></name><name name-style="western"><surname>Moultrie</surname><given-names>H</given-names></name><name name-style="western"><surname>Bekker</surname><given-names>LG</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G</given-names></name></person-group><article-title>Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa</article-title><source>N. Engl. J. Med</source><year>2022</year><volume>386</volume><fpage>494</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2119270</pub-id><pub-id pub-id-type="pmid">34965358</pub-id><pub-id pub-id-type="pmcid">PMC8757569</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>HF</given-names></name><etal/></person-group><article-title>Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1063</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01753-y</pub-id><pub-id pub-id-type="pmid">35189624</pub-id><pub-id pub-id-type="pmcid">PMC9117141</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>N</given-names></name><etal/></person-group><article-title>Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant</article-title><source>N. Engl. J. Med</source><year>2022</year><volume>386</volume><fpage>1532</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2119451</pub-id><pub-id pub-id-type="pmid">35249272</pub-id><pub-id pub-id-type="pmcid">PMC8908811</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><etal/></person-group><article-title>A comprehensive risk score for effective risk stratification and screening of nasopharyngeal carcinoma</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>5189</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-25402-z</pub-id><pub-id pub-id-type="pmid">34465768</pub-id><pub-id pub-id-type="pmcid">PMC8408241</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure</article-title><source>Science</source><year>2022</year><volume>377</volume><fpage>eabq1841</fpage><pub-id pub-id-type="doi">10.1126/science.abq1841</pub-id><pub-id pub-id-type="pmid">35699621</pub-id><pub-id pub-id-type="pmcid">PMC9210451</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>